

P D Home MA DPhil DM FRCP

For a 5-page manuscript biography see doi: 10.2337/dci21-0068 (*Diabetes Care*)

Background

Philip David HOME

born Birkenhead, UK 11 January 1948

British Citizen

married (1971) Elizabeth Broad MA DPhil (zoologist), two children (1976 and 1979)

Birkenhead School (1953-1966); Open Exhibition Corpus Christi College, Oxford (1966–1969)

Qualifications

B.A. (Oxon) 1969 – 2nd Class Honours in Animal Physiology

D.Phil. (Oxon) 1974

M.A. (Oxon) 1974

B.M., B.Ch. (Oxon) 1976

M.R.C.P. (U.K.) 1978

D.M. (Oxon) 1991

Current academic position

Newcastle University

Emeritus Professor (2020–)

Professor of Diabetes Medicine (1993–2020)

(Senior Lecturer 1986-1990, Reader 1990–1993)

Current NHS position

Newcastle upon Tyne Hospitals NHS Trust

Governor (Public (elected), honorary) (2021–)

Past employment (remunerated)

Newcastle upon Tyne Hospitals NHS Trust / Newcastle Primary Care Trust

Consultant Physician in Diabetes and Metabolic Medicine

(Honorary Newcastle HA 1984-1986, Established 1986–2011)

National Institute for Clinical Excellence

Vice-chairman Appraisal Committee (2004–2005, 2006–2011) (Member 1999–2003)

OTHER CURRENT/RECENT POSITIONS (with 5 years)

Consultancy (self or Newcastle University) 2016–2022

Merck (MSD), GlaxoSmithKline, Sanofi/Genzyme, Janssen R&D,

AstraZeneca, Roche Diagnostics, Ruijin Hospital/Shanghai JiaoTong University School of
Medicine, Kriya Therapeutics

Department of Health: see below for NICE and MHRA

Editorial Boards (current)

Diabetes Care (2018–2020)

Drug Investigation

Practical Diabetes International

Experimental and Clinical Endocrinology and Diabetes

Diabetes and the Metabolic Syndrome

Journal of Diabetology

Diabetes Research and Clinical Practice

MHRA

Clinical assessor, Research Applications (diabetes technologies) (2014–)

PAST SPECIAL POSITIONS AND HONOURS

Appointments and Lectureships

Wellcome Trust Senior Research Fellow in Clinical Science (1982–1986)

R D Lawrence Lecturer (British Diabetic Association, 1987)

British Diabetic Association / Diabetes UK

Medical and Scientific Section Committee (1987–1991)

Chairman, Manpower Group (1988–1996)

Diabetes Development Projects Committee (1984–1987)

Diabetes Information Management Advisory Group

(with Royal College of Physicians) (previously founding Chairman) (1992–1998)

Clinical Standards Advisory Service (1996–1998)

City University / University of London, London

External examiner in Medical Informatics (BSc and MSc) (1993–1998)

Consultancy, government (see also WHO(EMME))

Uzbekistan (health care) (1993–1999)

Turkmenistan (diabetes – ministerial advice) (1999)

Consultancy, industrial, 1982–2012 (for University of Newcastle)

(see also current)

Boehringer Ingelheim, Glaxo Wellcome, Hoechst Marion Roussel (Aventis), Eli Lilly, Novo Nordisk, Parke-Davis, Sanofi-Synthelabo (including chairmanship of International Advisory Boards)

Department of Health (UK / England and Wales)

Chair, Guidelines Advisory Group (Diabetes) (1993)

Clinical Standards Advisory Group – Diabetes (1992–1994)

Specialty consultant manpower planning (JPAC / SWAG) (1991–1995)

Chairman, NHS Research and Development Review in Diabetes (1995)

Chairman, Diabetes Outcomes Indicators Group (1996–1999)

Health Technology Review Group (2005–2006)

Health Related Groups (Diabetes and Endocrinology) Working Group (2000–2005; 2008–2011)

Danish Centre for Strategic Research in Type 2 Diabetes, Board (2010–2018)

Department of Health / British Diabetic Association Joint Task Force (1993–1995)

Information Group

Nephropathy Group

Research and Development Group

Department of Health / British Diabetic Association

Health-related Groups / Clinical Terms / Read Codes Working Party (Diabetes) (1992–1998)

Directorships (company / charity)

International Diabetes Federation Europe (1997–2000)

Diabetes Network International (2001–2005)

North East Diabetes Trust (1985–2018)

WorldWIDE Initiative for Diabetes Education, Board of Management (1999–2014; President 2004–2007)

Editorships (not current)

Diabetologia, Assistant Editor (1979–1980)

Diabetologia, Associate Editor (1981–1986)
 Diabetes Care, Editorial Board Member (1984–1986, 2018–2020)
 Diabetic Medicine, Editor (in Chief) (1987–1991), Deputy Editor (1983–1987), Board (1988–2008)
 Diabetes Voice, Editor in chief (2002–2004)
 Diabetes Research and Clinical Practice (European Editor) (1997–2001)
 European Association for the Study of Diabetes
 Honorary Secretary, Artificial Insulin Delivery and Pancreatic and Islet Transplantation, Study Group(1981–1986)
 Council member (1986–91, 1995–1997)
 Honorary Secretary, Education Committee (1986–1991)
 European Medical Research Councils, Network in Type 2 Diabetes (1991–1994)
 European Medicines Agency (EMA), Specialist Advisory Group Diabetes/Endocrinology, 2008
 Freeman Hospital NHS Trust – see Newcastle Hospitals NHS Trust
 International Diabetes Federation (global)
 Board of Management / Executive Board(1994–1997)
 Liaison person, World Health Organization (1995–1997)
 Organization and Economics of Care Track Chairman, 12th triennial meeting (2000)
 Editor-in-chief, *Diabetes Voice* (2002–2004), Editorial Board (1998–2001)
 Chair, World Diabetes Congress Programme Committee 2009 (2007–2009)
 Vice-President / Executive Board (1997–2003)
 Chairman, Clinical Guidelines Taskforce (1997–2007)
 Health Care Track Chairman, World Diabetes Congress, Montreal (2006)
 International Diabetes Federation (Europe)
 Chairman (1994–1997)
 Joint chair, Manager, European Diabetes Policy (Guidelines) Group (1998–2000)
 Medical Research Council / British Diabetic Association
 UK Prospective Diabetes Study Steering Committee (1989–1993)
 MHRA
 Expert Advisory Group Cardiovascular/Diabetes/Renal, Commission on Human Medicines (2006–2008), previously Committee for Safety of Medicines (external panel) (1992–2004)
 National Institutes of Health (USA)
 Cardiovascular Guidelines Working Group (2002)
 National Institute for Health and Clinical Excellence
 Vice-chairman Appraisal Committee (2004–2005, 2006–2011) (Member 1999–2003)
 NICE Appraisals Review clinical Effectiveness Group (2003, 2007)
 Clinical lead, NICE Type 2 Diabetes Guidelines (2005–8)
 Senior Scientific Advisor, Type 2 Diabetes Guidelines Group (NICE/DH) (1997–2002)
 Lead Clinical Advisor, NICE Type 1 Diabetes Guidelines Group (2001–2004)
 Guidelines Advisory Group, Rapid update (2008–9)
 Diabetes Quality and Indicators Groups (2010–2011)
 Scientific advice (2016)
 Newcastle Hospitals NHS Trust / Freeman Hospital
 Chairman, Research and Development Committee, Teaching Committee (Freeman Hospital) (1984–1988)
 Chairman, Clinical Trust Funds Research Advisory Committee (Freeman Hospital) (1995-98)
 Chairman, Medical Staff Committee (Freeman Hospital) (1999–2001, Vice-chairman 1997–1998)
 Management Executive, Clinical Governance Group, Clinical Policy Group, Drug and Therapeutics Committee

Discretionary Points Committee (1998–2001, 2003)
 Secretary, Division of Medicine (1992–1994)
 Audit Executive Group, Information Management Group, Clinical Risk Management Group (various years)
 Clinical Director, Medicine (1986–1988)

Newcastle University Hospitals Special Trustees Research Committee
 Newcastle and North Tyne Health Authority
 Clinical Effectiveness Working Party (1996–1998)
 Health care programmes working group (1997)

North of Tyne Strategic Health Authority, Newcastle and North Tyneside Health Authority
 Lipid prescribing advisory group (1998, 2000, 2002–4, 2006–2010)
 Diabetes Network, Local Diabetes Services Advisory Group / Diabetes Health Improvement Group (2000–2007)

Oxford University
 President, Oxford University Scientific Society (Michaelmas 1968)
 President, Committee of Middle Common Room Presidents (the postgraduate student representative body), Summer 1971
 Post-graduate student representative to Oxford University Library Committee (1971)

Royal College of Physicians
 Delegate, Department of Health Retinopathy Working Party (1992)
 Diabetes and Endocrinology Representative, Manpower Committee (1991–1995)
 Visitor, Joint Committee for Higher Medical Training (1987)
 Chairman, Committee for Endocrinology and Diabetes (Joint Specialty Committee 2000–) (1997– , honorary secretary 1993–1997, member 1991–2001)
 Specialty Advisory Board (1999–2001)
 Endocrinology and Diabetes Post-graduate Education Committee (1994–2001)
 Diabetes Accreditation Working Group (1998–2002)
 Various ad hoc working groups incl. Acute Medicine (1999)
 Diabetes guidelines, external advisor (2010–2011)
 NICE Type 2 diabetes guideline, lead clinical advisor (2005–2008)
 NICE Type 1 diabetes guideline, lead clinical advisor (2002–2004)

WHO
 Director (joint) (~1990–2011), WHO Collaborating Centre (Newcastle upon Tyne)
 Member, Diagnosis of Diabetes Guideline Group (2005–2007)

World Health Organisation
 Consultant (non-communicable disease), Mauritius, (1992)
 World Health Organization, Consultant (information technology in diabetes care), Malta, (1994)

WHO (Eastern Mediterranean Middle East) / Government of Kuwait
 Consultant on national diabetes programme (1996–1998)

WHO (Europe) / International Diabetes Federation (Europe) St Vincent Declaration Initiative
 WHO (Europe) / International Diabetes Federation (Europe) St Vincent Declaration Initiative
 DiabCare (Quality Development) Working Group (1989–1995)
 Steering Committee (1991–1995)
 Chairman Executive Group / Advisory Board (joint with Regional Director, WHO/Euro) (1995–1997)
 DiabCare (Quality Development) Working Group (1989–1995)
 Chairman, IDDM (insulin-dependent diabetes) Policy Group (1994)
 Visiting consultant Ministers of Health (Kazakhstan 1993, 1994, 1995), Uzbekistan (1994, 1995, 1996), Kyrgistan (1996), Azerbaijan (1996)

Chairman, Arterial Risk Factors Policy Group (1996–1997)
Programme Committee Member, 1999 10th anniversary meeting
Chairman/member, International Working Group / National Programmes Working Group
Co-ordinator, Diabetes Hypertension Guidelines Group (1999–2001)

University of Newcastle upon Tyne

Secretary, Nutrition Metabolism and Endocrinology Stage 2 Course (1993–1995)
Co-ordinator, Diabetes, Endocrinology and Metabolism Resource Days Teaching (1996)
Vice-chairman / member, Higher Degrees Committee (Medicine) (1996–1998)
Faculty Research Committee (Medicine, 1997–1998)

LEARNED SOCIETIES

Royal College of Physicians of London (1978– , Fellow 1989–)
Diabetes UK, formerly British Diabetic Association (1979–)
European Association for the Study of Diabetes (1980–)
American Diabetes Association (1983–)
International Diabetes Federation (1988–)

CHARITY AND COMPANY TRUSTEE / DIRECTORSHIPS

North East Diabetes Trust (1985–2018)
International Diabetes Federation Europe (1997–2000)
Diabetes Network International (2001–2003)
WorldWIDE Initiative for Diabetes Education (2004–2014)

MEDICAL AND ACADEMIC CAREER

Date	Post held	Location
April 1966– August 1966	Laboratory assistant (pharmaceuticals quality control)	Evans Medical Supplies, Liverpool
September 1966– March 1970	Undergraduate student	Oxford University Medical School and School of Natural Sciences
April 1970– April 1973	Medical Research Council Scholar	Department of Pharmacology Oxford University (Prof Sir WDM Paton)
May 1973– January 1976	Clinical medical student	Guy's Hospital Medical School
March 1976– August 1976	House Physician (Professor H Keen)	Guy's Hospital
September 1976– February 1977	House Surgeon	St Olave's Hospital
March 1977– August 1977	Senior House Officer (neurology)	Guy's Hospital
October 1977– September 1978	Senior House Officer (thoracic medicine, oncology, general medicine) Locum Senior Registrar (4 weeks), locum Registrar (2 weeks)	Guy's Hospital
November 1978– April 1979	Senior House Officer (cardiology)	London Chest Hospital
May 1979– August 1979	Research Fellow Honorary Registrar (Professor H Keen)	Unit for Metabolic Medicine, Guy's Hospital
September 1979– September 1981	Research Fellow (Prof K G M M Alberti) Honorary Registrar	Department of Clinical Biochemistry and Metabolic Medicine, University of Newcastle upon Tyne Newcastle Area Health Authority
October 1981– September 1982	Temporary First Assistant Newcastle upon Tyne Honorary Senior Registrar	Department of Clinical Biochemistry and Metabolic Medicine, University of Medical Unit 3, Freeman Hospital, Newcastle upon Tyne
October 1982– June 1986	Wellcome Trust Senior Fellow	Department of Clinical Biochemistry and Metabolic Medicine Department of Medicine from February 1985, University of Newcastle upon Tyne
October 1982– March 1984	Honorary Senior Registrar	Newcastle Health Authority
March 1984– June 1986	Honorary Consultant Physician	Newcastle Health Authority
June 1986– 2011	Consultant Physician	Newcastle Health Authority / Freeman Hospital NHS Trust / Newcastle Hospitals NHS Trust / Newcastle Primary Care Trust
June 1986– August 1990	Senior Lecturer	University of Newcastle upon Tyne
August 1990– April 1993	Reader in Diabetes Medicine	University of Newcastle upon Tyne
May 1993– Present	Professor of Diabetes Medicine (part-time 2012–2020; Emeritus 2020–)	University of Newcastle upon Tyne

TEACHING EXPERIENCE

Demonstrating to and tutoring of Oxford medical students in physiology and pharmacology (1970–1973)

Teaching ward rounds at Guy's and New Cross Hospitals for clinical medical students in general medicine and neurology (1977–1978)

Tutorials, lectures, and seminars for medical students in Newcastle upon Tyne (1979–)

Talks to British Diabetic Association parent and patient groups.

Teaching and lectures to many Postgraduate Meetings (local, hospital, regional, national, international, Royal Collage, professional associations):

- including (2007–2013) at American, Australian, Asian Endocrine, Columbian, Canadian, Indian, Indonesian, Middle East, Saudi Arabian, and many other national and international diabetes congresses, on subjects related to optimal insulin and drug therapy, organization of care, international guidelines, international care initiatives

Scripting and presentations of part of the BBC Open University television programme 'Diabetes: Restoring the Balance'.

Honorary Secretary, Post-graduate Education Sub-committee, European Association for the Study of Diabetes (1986–1991)

Member, Steering Group, English National Board Course in Diabetes, Newcastle upon Tyne (1988–1994)

Organiser, Advanced Postgraduate Course in Diabetes, Newcastle upon Tyne (1990–1992)

Organiser, Advanced Nursing Course in Diabetes, Newcastle upon Tyne (1989)

Secretary, Stage 2 Nutrition, Metabolism, and Endocrinology Course, Medical School, University of Newcastle upon Tyne (1991–1995)

Organizing Chairman, Central Asia International Diabetes Seminars (Kazakhstan/Uzbekistan 1994; Kazakhstan/Uzbekistan 1995; Kazakhstan/Kyrgistan/Uzbekistan 1996; Azerbaijan 1996)

Programme Committee Member of many national / international meetings (recently including the WHO/IDF Tenth Anniversary St Vincent Declaration Initiative meeting Istanbul, 1999, and 12th IDF Triennial Congress (Chair, Organization and Economics of Care Track), Mexico City, 2000, 13th World Diabetes Congress, Cape Town, 2006, CODHy meetings (various 2008–)

Founding Chair, WorldWide Initiative for Professional Diabetes Education (2000–2004), President (2004–2007), Board of Directors (2004–2015)

Programme Chair, World Diabetes Congress, International Diabetes Federation, Montreal, 2009.

Interviewer and webcast anchor, Medscape (2009–2015)

Lecturing 2017–2022

2017

Controversies in Obesity, Diabetes and Hypertension Latin America, Buenos Aires, lectures x4 and session chair x2

Site-less Clinical Trials webinar, April, talk

American Diabetes Association, San Diego, June: poster presentations; webinar presentations x2

Korean Diabetes Association, Seoul, October, plenary lecture and guidelines presentation

International Congress on Controversies in Primary and Outpatient Care, Zagreb, October, lecture/debate

Mumbai, Kolkatta, Delhi, July, lectures (commercially sponsored)

Thailand Endocrine Society, Bangkok, lecture. Commercially sponsored talks in Taipei, Taiwan, and for Hong Kong (x2)

Metabesity, London, October, lecture

World Clinical Trials in Diabetes, Berlin, November, lecture x2

International Diabetes Association World Diabetes Congress, Abu Dhabi, poster

EASD Clinical Trials Study Group, Munich, lecture

2018

Gulf Group for the Study of Diabetes, Kuwait, March, plenary and workshop invited lectures

Worldwide Initiative for Diabetes Education (at Korean Endocrine Society annual meeting), Seoul, April, programme and meeting chair

Controversies in Obesity, Diabetes, Hypertension Asia Congress, Shanghai, May, invited speaker, session chair

International Centre for Parliamentary Studies, Diabetes Europe Roundtable, Brussels, May, programme and meeting chair

European Association for the Study of Diabetes & Cardiovascular Disease Study Group, Herzliya (Tel Aviv), May, invited plenary lecture, session chair

American Diabetes Association Annual Meeting Scientific Sessions, Orlando, June, poster author (x2)

European Academy for Continuing Medical Education, September, weblecture

European Association for the Study of Diabetes Annual Meeting, Berlin, October, invited speaker (x2), poster author, session chair (x2)

CAD Conference, Mumbai, October, lectures (x4) and session chair (x2)

European Association for the Study of Diabetes & Cardiovascular Disease Study Group, Munich, October, plenary lecture

Brazilian Society for Diabetes, lectures and closing plenary lecture, Brasilia, November

Novo Nordisk (Saudi Arabia) training meeting, Bahrain, November, lecture x3

World Clinical Trials in Diabetes, Vienna, November, programme organizer, lecture, chair

2019

Fourth Pan-African Congress of Diabetes, Yaoundé, April, invited plenary lecturer and lecturer, session chair

Controversies in Obesity, Diabetes, and Hypertension, Sorrento, April, invited speaker, programme committee, session chair

International Centre for Parliamentary Studies, Diabetes Europe Roundtable, Brussels, May, chair, programme and meeting

Controversies in Obesity, Diabetes, Hypertension Asia Congress, Shanghai, May, invited speaker (x3), session chair

Commercial invitations (AstraZeneca, China) Beijing and Suzhou, May 2018

American Diabetes Association Annual Meeting, invited speaker, San Francisco, June

European Association for the Study of Diabetes, Barcelona, September invited speaker (x2),

National Institute for Diabetes, Diabetes Asia Conference, Kuala Lumpur, October, invited lectures (x3)

2nd Metabesity Congress, Washington DC, October, invited speaker

World Clinical Trials in Diabetes, Amsterdam, November, programme chairman, invited speaker, session chair

World Diabetes Congress (International Diabetes Federation), Busan, December, invited speaker (since declined the invitation)

International symposium ((Pirogov Russian National Research Medical University), Moscow, December, invited lectures (x2), session chair

2020

East Africa Diabetes Study Group, Entebbe, February, invited lectures (x2)

Gulf Group for the Study of Diabetes, Muscat, March, invited lectures (x3) [cancelled]

Controversies in Obesity, Diabetes, Hypertension Asia Congress, Shanghai, May, invited speaker (virtual)

European Academy for CME (for India), June, virtual lecture

Novartis, Malaysia, June, virtual lecture

American Diabetes Association Annual Meeting, invited speaker, lecture (virtual)

ABCD annual meeting (virtual)

Metabesity, Washington, panel member (virtual)

2021

DiabetesIndia, June (virtual lecture)

Association of British Clinical Diabetologists, November (virtual)

Metabesity, Washington (panellist, virtual)

Diabetes Professional Conference, London, October, invited speaker

2022

CODHy Asia, Session Chair

Association of British Clinical Diabetologists, invited speaker, July (virtual)

National Institute for Diabetes, Diabetes Asia Conference, Kuala Lumpur, October, invited lecture (virtual), November

Diabetes India, May (virtual lecture)

2023

East Africa Diabetes Study Group, Dar es Salaam, April, invited lectures (x2)

Gulf Group for the Study of Diabetes, Jeddah, invited lectures (x2)

EASD Study Group Diabetes and CV Disease, Tel Aviv, invited lecture

RESEARCH

Please review the research output in my bibliography that follows. For summary of interests see my website.

Citation statistics (Google Scholar, January 2023)

	All	Since 2018
Citations	31907	9717
h-index	76	44
i10-index	274	128

PUBLICATIONS (excludes meeting abstracts)

D Phil Thesis - 1974

1. Home PD. Studies on peptidase enzymes in the central nervous system. D Phil Thesis (Oxford University), 1974.

Reviewed articles - 1981

2. Home PD, Pickup JC, Keen H, Alberti KGMM, Parsons JA, Binder C. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose. *Metabolism* 1981; 30: 439-442.
3. Pickup JC, Home PD, Bilous RW, Keen H, Alberti KGMM. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusion: evidence for a defect in subcutaneous insulin absorption. *Br Med J* 1981; 282: 347-350.
4. Viberti GC, Strakosch CR, Keen H, MacIntosh D, Dalton N, Home PD. The influence of glucose induced hyperinsulinaemia on renal glomerular function and circulating catecholamines in normal man. *Diabetologia* 1981; 21: 436-439.
5. Taylor Roy, Home Philip D, Alberti K George MM. Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. *Diabetes Care* 1981; 4: 377-379.
6. Owens DR, Jones MK, Hayes TM, Heding LG, Alberti KGMM, Home PD, Burrin JM, Newcombe RG. Human insulin: a study of safety and efficacy in man. *Br Med J* 1981; 282: 1264-1266.
7. Owens DR, Jones MK, Hayes TM, Heding LG, Alberti KGMM, Home PD, Burrin JM. Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin. *Lancet* 1981; ii: 118-122.

Reviewed articles - 1982

8. Home PD, Massi-Benedetti M, Gill GV, Capaldo B, Shepherd GAA, Alberti KGMM. Impaired subcutaneous absorption of insulin in 'brittle' diabetics. *Acta Endocrinologica* 1982; 101: 414-420.
9. Home PD, Massi-Benedetti M, Shepherd GAA, Hanning I, Alberti KGMM, Owens DR. A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique. *Diabetologia* 1982; 22: 41-45.
10. Pickup JC, Viberti GC, Bilous RW, Keen H, Alberti KGMM, Home PD, Binder C. Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. *Diabetologia* 1982; 22: 175-179.
11. Nosadini R, Noy GA, Nattrass M, Alberti KGMM, Johnston DG, Home PD, Ørskov H. The metabolic and hormonal response to acute normoglycaemia in Type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas). *Diabetologia* 1982; 23: 220-228.
12. Worth R, Home PD, Johnston DG, Anderson J, Ashworth Linda, Burrin Jacqueline M, Appleton D, Binder C, Alberti KGMM. Intensive attention improves glycaemic control in insulin dependent diabetes without further advantage from home blood glucose monitoring: results of a controlled trial. *Br Med J* 1982; 285: 1233-1240.
13. Owens DR, Jones MK, Birtwell J, Hayes TM, Heding LG, Vølund A, Alberti KGMM, Home PD. A study of the comparative safety and efficacy of neutral soluble human (semi-synthetic) and porcine monocomponent insulin in non-diabetic subjects. *Diabete Metabol* 1982; 8: 155-158.

14. Home PD, Capaldo B, Burrin JM, Worth R, Alberti KGMM. A cross-over comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. *Diabetes Care* 1982; 5: 466-471.
15. McCulloch AJ, Home PD, Heine R, Ponchner M, Hanning I, Johnston DG, Clark F, Alberti KGMM. Insulin sensitivity in hyperthyroidism: measurement by the glucose clamp technique. *Clin Endocrinol* 1983; 18: 327-333.

Invited articles - 1982

16. Alberti KGMM, Worth R, Home PD, Johnston DG, Anderson J, Burrin JM, Ashworth L. Home blood glucose monitoring: does it improve diabetic control per se? In: Peterson CM (ed). *Diabetic management in the 80's* New York: Praeger 1982: 298-305.
17. Home PD, Alberti KGMM. The new insulins: their characteristics and clinical indications. *Drugs* 1982; 24: 401-413.
18. Home Philip D, Alberti KGMM, Owens David R. Some observations on insulin absorption and pharmacokinetics. In: Skyler J (ed), *Insulin update 1982*. Amsterdam: Excerpta Medica 1982, 120-124.
19. Alberti KGMM, Home PD. Monitoring of insulin therapy in insulin dependent diabetes mellitus. In: Skyler JS (ed), *Insulin update 1982*. Amsterdam: Excerpta Medica, 1982, 175-184.
20. Alberti KGMM, Home PD, Johnston DG, Nattrass M. Good control of insulin-dependent diabetes; a dream or reality? *Diabetologia Croatia* 1982; 5: 466-471.
21. Home PD, Alberti KGMM. Human insulin. *Clinics in Endocrinology and Metabolism* 1982; 11: 453-481.

Reviewed articles - 1983

22. Home PD, Shepherd GAA, Noy G, Massi-Benedetti M, Hanning I, Burrin JM, Alberti KGMM. Comparison of the activity and pharmacokinetics of porcine insulin and human insulin (NOVO) as assessed by the glucose clamp technique in normal diabetic man. *Diabetes Care* 1983; 6 (suppl 1): 23-28.
23. Francis AJ, Home PD, Hanning I, Alberti KGMM, Tunbridge WMG. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. *Br Med J* 1983; 286: 1173-1176.
24. Worth R, Ashworth L, Home PD, Gerrard J, Lind T, Anderson J, Alberti KGMM. Glycosylated haemoglobin in cord blood following normal and diabetic pregnancies. *Diabetologia* 1983; 25: 482-485.

Invited articles - 1983

25. Home PD. The artificial pancreas and continuous insulin infusion. In: Dinwoodie M (ed), *Proceedings of the Guild*. London: Guild of Hospital Pharmacists, 1983, 60-61.
26. Viberti GC, Bilous RW, Pickup JC, Keen H, Home PD, Alberti KGMM. Metabolic, hormonal, cardiovascular and renal response to physical exercise in insulin-dependent diabetes: effect of normoglycaemia induced by subcutaneous insulin infusion. In: Brunetti P, Alberti KGMM, Albisser AM, Hepp KD, Massi-Benedetti M (ed), *Artificial systems for insulin delivery*. New York: Raven, 1983, 233-237.
27. Home PD, Capaldo B, Nosadini R, Massi-Benedetti M, Burrin JM, Noy GA, Nattrass M, Johnston DG, Alberti KGMM. Studies on intermediary metabolism using closed-loop control of blood glucose concentrations. In: Brunetti P, Alberti KGMM, Albisser AM, Hepp KD, Massi-Benedetti M (ed), *Artificial systems for insulin delivery*. New York: Raven, 1983, 505-512.

28. Home PD, Gill GV, Alberti KGMM. Clinical applications of open-loop systems. In: Brunetti P, Alberti KGMM, Albisser AM, Hepp KD, Massi-Benedetti M (ed), *Artificial systems for insulin delivery*. New York: Raven, 1983: 191-198.
29. Home PD, Capaldo B, Alberti KGMM. The quality of metabolic control during open-loop insulin infusion in Type 1 diabetics. Mngola EN (ed), *Diabetes. International Congress Series 600*. Amsterdam: Excerpta Medica, 1983, 295-301.
30. Home PD and Alberti KGMM. The new insulins: characteristics and clinical indications. *New Ethicals* 1983; 1: 167-183.
31. Alberti KGMM, Home PD, Capaldo B, Nosadini R, Stevenson R. Insulin delivery systems and metabolic control. In: Sakamoto N, Alberti KGMM (ed), *Current and future therapies with insulin*. Amsterdam: Excerpta Medica, 1983, 20-32.

Reviewed articles - 1984

32. Viberti GC, Home PD, Bilous RW, Alberti KGMM, Dalton N, Keen H, Pickup JC. Metabolic effects of physical exercise in insulin-dependent diabetics controlled by continuous subcutaneous insulin infusion or conventional injection therapy. *Acta Endocrinol* 1984; 105: 515-520.
33. Elliott Martin J, Gill Geoffrey V, Home Philip D, Noy George A, Holden Michael P, Alberti K George MM. A comparison of two regimens for the management of diabetes during open-heart surgery. *Anesthesiol* 1984; 60: 364-368.
34. Walford S, Home PD, Alberti KGMM. A laboratory trial of two new blood-glucose reflectance meters featuring automatic external calibration. *Ann Clin Biochem* 1984; 21: 116-119.
35. Capaldo B, Home PD, Massi-Benedetti M, Worth R, Cook DB, Heaton A, Alberti KGMM. The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in Type 1 diabetes. *Diabetes Res* 1984; 1: 187-193.
36. Home PD, Mann NP, Hutchison AS, Park R, Walford S, Murphy M, Reeves WG. A fifteen month double blind cross-over study of the efficacy and antigenicity of human and pork insulins. *Diabetic Med* 1984; 1: 93-98.
37. Heine RJ, Ponchner M, Hanning I, Home PD, Brown M, Williams D, Alberti KGMM. A comparison of the effects of semisynthetic human insulin and porcine insulin on transmembrane ion shifts and glucose metabolism during euglycaemic clamping. *Acta Endocrinol* 1984; 106: 241-247.
38. Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. *N Engl J Med* 1984; 311: 365-372.

Invited articles - 1984

39. Home PD, Marshall SM. Problems and safety of continuous subcutaneous insulin infusion. *Diabetic Med* 1984; 1: 41-44.
40. Home PD, Walford S. Diabetes care - whose responsibility? (Editorial). *Br Med J* 1984; 289: 713-714.
41. Owens DR, Heding LG, Birtwell AJ, Jones IR, Home PD, Luzio S. Clinical studies with 'semi-synthetic' human insulin. In: Sakamoto N, Alberti KGMM (ed), *Current and future therapies with insulin*. International Congress Series 607. Amsterdam: Excerpta Medica, 1984, 90-97.

Reviewed articles - 1985

42. Francis AJ, Home PD, Walford S, Alberti KGMM, Mann N, Reeves WG. Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics. *Diabetic Med* 1985; 2: 89-94.
43. Home PD, Gill GV, Husband D, Kruszynska YT, Marshall S, Alberti KGMM. Alternative routes and methods of insulin delivery. *Neth J Med* 1985; 28 (suppl 1): 32-36.
44. Lawson P, Home PD, Bergenstal R. Observations on blood and intermediary metabolite concentrations during conventional insulin treatment or continuous subcutaneous insulin infusion. *Diabetes* 1985; 34 (suppl 3): 27-30.
45. Home Philip D, Alberti K George MM, Rodger N Wilson, and Burrin Jacqueline M. The central biochemistry laboratory in the multicenter Kroc study: problems and proposals. *Diabetes* 1985; 34 (suppl 3): 17-21.
46. Kruszynska YT, Home PD, Alberti KGMM. Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. *Diabetologia* 1985; 28: 167-171.
47. Kruszynska YT, Home PD, Alberti KGMM. Comparison of portal and peripheral insulin delivery on lipid metabolism in streptozotocin-diabetic rats. *Diabetes* 1985; 34: 611-616.
48. Kroc Collaborative Study Group. Collaborative studies of the effects of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. *Diabetes* 1985; 34 (suppl 3): 87-89.
49. Heine RJ, Home PD, Ponchner M, - Ørskov H, Hammond V, McCulloch AJ, Hanning I, Alberti KGMM. A comparison of three methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance. *Diabetes Res* 1985; 2: 113-120.
50. Hanning I, Home PD, Alberti KGMM. Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies. *Diabetologia* 1985; 28: 831-835.
51. Jimenez JT, Walford S, Home PD, Hanning I, Alberti KGMM. Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients. *Diabetologia* 1985; 28: 728-733.
52. Royal College of Physicians of London and British Diabetic Association. The provision of medical care for adult diabetic patients. London: Royal College of Physicians, 1985.
53. Almer L-O, Ekberg G, Fankhauser S, Home PD, Worth R, Sailer S, Kurtz AB, Christy M. A prospective study of the immunogenicity of porcine insulin in the HLA-typed new insulin treated diabetic. *Diabetes Res* 1985; 2: 221-224.

Invited articles - 1985

54. Home PD. Management of diabetes with insulin. *Medicine International 2nd Series* 1985; 13: 538-541.
55. Gill Geoffrey V, Husband David J, Walford Simon, Marshall Sally M, Home Philip D, Alberti K George MM. Clinical Features of brittle diabetes. In: John C Pickup (ed), *Brittle diabetes*. Oxford: Blackwell Scientific 1985, 29-40.
56. Home Philip D, Gill Geoffrey V, Husband David J, Massi-Benedetti Massimo, Marshall Sally M, Alberti K George MM. Hormonal and metabolic abnormalities. In: John C Pickup (ed), *Brittle diabetes*. Oxford: Blackwell Scientific, 1985, 167-180.
58. Home PD, Francis AJ, Owens DR. Farmacologica clinica y farmacocinetica comparada de la insulina humana. In: Serrano Rios M, Guijo J, Vizcaino J (ed), *Simposio Diabetologico Sobre*. Madrid: Nordisk Gentoftte A/S, 1985, 37-42.
59. Home PD, Alberti KGMM. Infusion subcutanea continua de insulina: su efecto en la retinopatía y nefropatía establecidas. In: Serrano Rios M, Guijo J, Vizcaino J (ed), *Simposio diabetologico sobre*. Madrid: Nordisk Gentoftte, 1984.
60. Alberti KGMM, Home PD, Capaldo B, Falholt K, Husband DJ, Kruszynska Y, Marshall SM, Nosadini R, Stevenson RW. Influence of delivery routes of insulin on intermediary

metabolism. Diabetes, obesity and hyperlipidaemias - III. In: Crepaldi G et al (ed), Proceedings of the 4th European symposium on metabolism. Amsterdam: Excerpta Medica, 1985, 417-426.

61. Home PD. Providing motivation for better diabetic care (editorial). *Diabetic Med* 1985; 2: 435-436.

Reviewed articles - 1986

62. Kruszynska YT, Home PD, Agius L, Alberti KGMM. Hepatic glycogen metabolism and insulin receptor status after long-term peripheral insulin delivery in the islet-transplanted diabetic rat. *Diabetes* 1986; 35: 306-310.
63. de Beaufort CE, Bruining GJ, Home PD, Houtzagers CMGJ, van Strik R. Overnight metabolic profiles in very young insulin-dependent diabetic children. *Eur J Pediatr* 1986; 145: 73-76.
64. Kruszynska YT, Home PD, Alberti KGMM. In vivo regulation of liver and skeletal muscle glycogen synthase activity by glucose and insulin. *Diabetes* 1986; 35: 662-667.
65. Kruszynska YT, Home PD, Morley A, Alberti KGMM. Preservation of islet function and morphology after transplantation into high dose streptozotocin-diabetic rats. *Diabetes Research* 1986; 3: 175-181.
66. Kruszynska YT, Petronyi G, Home PD, Taylor R, Alberti KGMM. Muscle enzyme activity and insulin sensitivity in Type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1986; 29: 699-705.

Invited articles - 1986

67. Marshall SM, Home PD. Which pump? *Diabetic Med* 1986; 3: 190-191.
68. Anonymous (Editorial). A physiological basis for dietary assessment in diabetes? *Lancet* 1986; i: 720-721.
69. Home PD (Editorial). 'Diabetes first', complications second. *Diabetic Med* 1986; 3: 409-410.
70. Home PD. Management of diabetes in surgery. *I quaderni di metabolismo* 1986; 3 (suppl 1): 59-63.
71. Home PD, Alberti KGMM. Continuous subcutaneous insulin infusion: influence on established retinopathy and nephropathy. *The Physician India* 1986; 3: 440-444.

Reviewed articles - 1987

72. Steel JM, Home PD, Young RJ, Johnstone FD, Frier BM. Observations on the metabolic basis for altered insulin dose distribution in diabetic pregnancy. *Diabetes Res Clin Pract* 1987; 3: 1-7.
73. Kruszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-h C-peptide and insulin secretion rate in normal man. *Diabetologia* 1987; 30: 16-21.
74. Kruszynska YT, Home PD, Alberti KGMM. Very low density lipoprotein metabolism after insulin over-treatment and during euglycaemic clamp. *European Journal of Clinical Investigation* 1987; 17: 23-28.
75. Kruszynska YT, Home PD, Alberti KGMM. Insulin insensitivity and skeletal muscle enzyme activities in response to overinsulinization in the rat. *Metabolism* 1987; 36: 281-285.
76. Home PD, Tunbridge WMG. Appointments and turnover of consultants and senior registrars in diabetes and endocrinology in the UK, 1984 and 1985. *Diabetic Med* 1987; 4: 19-82.
77. Kruszynska YT, Home PD. Lipid metabolism in rat models of causes of hyperinsulinaemia in insulin treated man. *Diabete Metabol* 1987; 13: 386-389.

78. Massi-Benedetti M, Home PD, Gill GV, Burrin JM, Noy GA and Alberti KGMM. Hormonal and metabolic responses in brittle diabetic patients during feedback intravenous insulin infusion. *Diabetes Res Clin Pract* 1987; 3: 307-317.
79. Marshall SM, Home PD, Taylor R, Alberti KGMM. Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. *Diabetic Med* 1987; 4: 521-525.
80. Kruszynska YT, Greenstone M, Home PD, Cooke N. High dose inhaled beclomethasone dipropionate disturbs carbohydrate and lipid metabolism in normal subjects. *Thorax* 1987; 42: 881-884.
81. Home PD, Tunbridge WMG. The changeover to U100 insulin in the United Kingdom. *Neth J Med* 1987; 31: 191-199.
82. Davis SN, Butler PC, Brown MD, Beer S, Sobey W, Helas CN, Home PD, Alberti KGMM. The effects of biosynthetic human proinsulin on intermediary metabolism. *Biochem Soc Transact* 1987; 15: 1054-1055.

Invited articles - 1987

83. Home PD. Human insulin in clinical practice. *Practical Cardiology* 1987; 13(2): 65-80.
84. Home PD, Alberti KGMM. Biosensors in medicine: the clinician's requirements. In: Turner Anthony PF, Karube Isao, Wilson George S (ed), *Biosensors - fundamentals and applications*. Oxford: Oxford University, 1987, 723-735.
85. Alberti KGMM, Home PD. Diabetic complications: the importance of metabolic control in man. In: Sakamoto N, Alberti KGMM, Hotta N (ed), *Recent trends in management of diabetes mellitus*. Amsterdam: Elsevier Science, 1987, 8-15.
86. Marshall SM, Alberti KGMM, Home PD. Continuous subcutaneous insulin infusion: problems encountered in clinical usage. In: Sakamoto N, Alberti KGMM, Hotta N (ed), *Recent trends in the management of diabetes mellitus*. Amsterdam: Elsevier Science, 1987, 123-129.
87. Kruszynska YT, Home PD, Petranyi G, Taylor R, Alberti KGMM. Skeletal muscle metabolism and blood intermediary metabolite concentrations in insulin treated diabetes. In: Brunetti P, Waldhäusl WK (ed), *Advanced models for the therapy of insulin-dependent diabetes*. New York: Raven, 1987, 53-57.
88. Home PD. What went wrong? A guide to designing a useful clinical research study before too late. *Practical Diabetes* 1987; 4: 4-43.
89. Anonymous. When to consider continuous subcutaneous insulin infusion (CSII). *Drug Therapeut Bull* 1987; 25: 25-28.
90. Kruszynska YT, Home PD. Insulin insensitivity in type 1 diabetes. *Diabetic Med* 1987; 4: 414-422.
91. Home PD. Insulin injection therapy. In: Alberti KGMM, Krall LP (ed), *The Diabetes Annual 3*. Amsterdam: Elsevier, 1987, 94-106.
92. Home PD (Editorial). Spreading the message. *Diabetic Med* 1987; 4: 97-98.
93. Anonymous (Editorial, with Marshall SM). Provision of renal replacement therapy for diabetic patients in the United Kingdom. *Lancet* 1987; ii: 21-22.
94. Butler PC, Home PD. The measurement of metabolic exchange across muscle beds. In: Alberti KGMM, Home PD, Taylor R (ed), *Techniques of metabolic measurement in man*. London: Balliere Tindall, 1987, 863-878.

Book edited - 1987

95. Alberti KGMM, Home PD, Taylor R (ed). *Techniques for metabolic investigation in man*. Clinical Endocrinology and Metabolism. London: Baillière Tindall, 1987.

Reviewed articles - 1988

96. Marshall SM, Taylor R, Home PD, Alberti KGMM. Intermediary metabolism, insulin sensitivity and insulin receptor status under comparable long-term therapy with insulin injections and continuous subcutaneous insulin infusion. *Acta Endocrinol* 1988; 117: 417-427.
97. Kruszynska YT, Home PD. Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. *Diabete Metabol* 1988; 14: 437-442.
98. Home PD. Techniques for ensuring that your next paper is quite unsuitable for publication. *J Roy Coll Phys* 1988; 22: 48-50.
99. Kruszynska YT, Williams NW, Perry M, Home PD. The relationship between insulin sensitivity and skeletal muscle enzyme activities in hepatic cirrhosis. *Hepatology* 1988; 8: 1615-1619.
100. Kruszynska YT, Home PD. Liver and muscle insulin sensitivity, glycogen concentration and glycogen synthase activity in a rat model of non-insulin dependent diabetes. *Diabetologia* 1988; 31: 304-309.
101. Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of The Kroc Collaborative Study. *J Am Med Assoc* 1988; 260: 37-41

Invited articles - 1988

102. Home PD. Insulin injection therapy. In: Alberti KGMM, Krall LP (ed), *The Diabetes Annual* 4. Amsterdam, Elsevier, 1988, 92-102.
103. Home PD (Editorial). The OGTT: Gold that Does not Shine. *Diabetic Med* 1988; 5: 313-314.
104. Home PD (Editorial). Driven to Abstraction. *Diabetic Med* 1988; 5: 419-420.

Reviewed articles 1989

105. Tunbridge FKE, Newens A, Home PD, Davis SN, Murphy M, Burrin JM, Alberti KGMM, Jensen I. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens. *Diabetes Care* 1989; 12: 115-119.
106. Thow JC, Johnson AB, Antsiferov M, Home PD. Exercise augments the absorption of isophane (NPH) insulin. *Diabetic Med* 1989; 6: 342-345.
107. Thow JC, Johnston AB, Antsiferov M, Home PD. Effect of raising injection site-skin temperature on isophane (NPH) insulin crystal dissociation. *Diabetes Care* 1989; 12: 432-434.
108. Tunbridge FKE, Newens A, Home PD, Davis SN, Murphy M, Burrin JM, Alberti KGMM, Jensen I. A comparison of human ultralente and lente-based twice daily injection regimen. *Diabetic Med* 1989; 6: 496-501.

Invited articles - 1989

109. Home PD (Editorial). Towards the ultimate outcome. *Diabetic Med* 1989; 6: 11-12.
110. Home PD, Johnston DG, Alberti KGMM. Diabetes Mellitus. In: Hall R, Besser M (ed), *Fundamentals of clinical endocrinology*. Edinburgh: Churchill Livingstone, 1989, 318-361.
111. Home PD, Thow JC, Tunbridge FKE. Insulin treatment: a decade of change. *Br Med Bull* 1989; 45: 92-110.
112. Home PD (Editorial). Dangers for the future of diabetes care. *Diabetic Med* 1989; 6: 101-102.
113. Home PD (Editorial). Is it time to restructure medical training in diabetes? *Diabetic Med* 1989; 6: 193-194.
114. Home PD (Editorial). Replacing insulin injections. *Diabetic Med* 1989; 6: 289-290.

115. Home PD (Editorial). Type 2 diabetes and Reaven's syndrome. *Diabetic Med* 1990; 6: 559-560.
116. Home PD (Editorial). Diabetic medicine. *Diabetic Med* 1989; 6: 753.
117. Home PD. Model care 1989: some thoughts from the United Kingdom. In: Alberti KGMM, Mazze R (ed), *Frontiers of diabetes research; current trends in non-insulin-dependent diabetes mellitus*. Excerpta Medica, Amsterdam, 1989, 215-223.

Reviewed articles - 1990

118. Thow JC, Johnson AB, Fulcher G, Home PD. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. *Diabetic Med* 1990; 7: 600-602.
119. Goodship THJ, Butler PC, Rodham D, Clayton B, Home PD, Alberti KGMM. Total-body potassium in insulin-dependent diabetes mellitus. *Clin Sci* 1990; 78: 377-381.
120. Tunbridge WMG, Home PD. Manpower changes in diabetes and endocrinology in the UK, 1985-1990. *Diabetic Med* 1990; 7: 833-837.
121. EURODIABETA. Information technology in diabetes care in Europe: the EURODIABETA initiative. *Diabetic Med* 1990; 7: 639-650.
122. Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin. *Diabetic Med* 1990; 7: 795-799.

Invited articles - 1990

123. Taylor R, Home PD. The practical management of insulin resistance. In: Tattersall RB, Gale EAM (ed), *Diabetes: clinical management*. Churchill Livingstone, Edinburgh, 1990, 245-249.
124. Home PD, Gill GV. Management of diabetes in special situations: surgery, pancreatotomy and steroid treatment. In: Tattersall RB, Gale EAM (ed), *Diabetes: clinical management*. Churchill Livingstone, Edinburgh, 250-259.
125. Home PD (Editorial). EASD growing pains. *Diabetic Med* 1990; 7: 8-9.
126. Home PD (Editorial). Diabetes, the 1980's, and beyond. *Diabetic Med* 1990; 7: 97-98.
127. Home PD (Editorial). COMAtose; or a report on sugar. *Diabetic Med* 1990; 7: 197-198.
128. Home PD, Thow JC, Tunbridge FKE. Insulin treatment: a decade of change. *Br Med Bull* 1990; 45: 92-110.
129. Home PD, Thow JC. Insulin injection therapy. In: Alberti KGMM, Krall LP (ed), *The Diabetes Annual 5*. Amsterdam: Elsevier 1990: 152-165.
130. Home PD. Monitoring of control in type II diabetes. *Diabetes Nutrit Metabol* 1990; 3(suppl 1): 23-28.
131. Home PD (Editorial). Glycosylated haemoglobin revisited. *Diabetic Med* 1990; 7: 385-386.
132. Thow J, Home P (Editorial). Insulin injection technique. *Br Med J* 1990; 301: 3-4.
133. Tunbridge FKE, Home PD, Newens A, Alberti KGMM, Murphy M. Clinical experience of human insulin. In: Sakamoto N, Alberti KGMM, Hotta N (ed). *Current status of prevention and treatment of diabetic complications*. Excerpta Medica: Amsterdam 1990: 243-251.
134. Home PD. Alternative methods and routes of insulin delivery. In: Pickup JC, Williams G (ed), *Textbook of diabetes*. Oxford: Blackwell Scientific, 1990, 442-452.
135. Home PD. Glycated proteins in clinical practice. In: RG Ryall (ed), *Glycated proteins in diabetes mellitus*. Adelaide, Adelaide Children's Hospital, 1990, 62-75.

Reviewed articles - 1991

136. Marsiaj HI, Catalano C, Sum CF, Home PD, Alberti KGMM. Management of newly diagnosed non-insulin-dependent (type 2) diabetes mellitus: a retrospective audit. *Diabetes Res Clin Pract* 1991; 12: 129-136.
137. Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. *Hepatology* 1991; 14: 103-111.
138. Reboldi GP, Home PD, Calabrese G, Fabietti PG, Brunetti P, Massi Benedetti M. Time delay compensation for closed-loop insulin delivery systems: a simulation study. *Int J Artificial Org* 1991; 14: 350-358.
139. Tunbridge FKE, Home PD, Murphy M, Alberti KGMM. Does flexibility at mealtimes disturb blood glucose control on a multiple insulin injection regimen. *Diabetic Med* 1991; 8: 833-838.
140. Davis SN, Thompson CJ, Brown MD, Home PD, Alberti KGMM. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. *Diabetes Res Clin Pract* 1991; 13: 107-118.
141. Davis SN, Butler PC, Brown M, Beer S, Sobey W, Hanning I, Home PD, Hales CN, Alberti KGMM. The effects of human proinsulin on glucose turnover and intermediary metabolism. *Metabolism* 1991; 40: 953-961.

Invited articles - 1991

142. Anonymous (Editorial with Robertson DA). Insulin resistance in puberty. *Lancet* 1991; 337: 1259-1260.
143. Home PD. Language and learning in diabetes care (Editorial). *Diabetic Med* 1991; 8: 504-504.
144. Home PD. Audit of diabetic care (Editorial). *Hospital Update* 1991; 623-624.
145. Home PD. Hypoglycaemia unawareness and human insulin. The UK experience. In: K Federlin, H Keen, H Mehnert (ed), *Hypoglycaemia and human insulin*. Stuttgart: Georg Thieme Verlag, 1991, 151-159.
146. Home PD. Diabetes and the number revolution (Editorial). *Diabetic Med* 1991; 8: 400-401.
147. Thow JC, Home PD. Insulin injection therapy. In, Alberti KGMM, Krall L (ed), *Diabetes Annual 6*. Amsterdam: Elsevier, 1991, 148-168.
148. Home PD. The most important diabetic clinic (Editorial). *Diabetic Med* 1991; 8: 96.
149. Bradley C, Home P, Christie M. Medical and psychosocial perspectives on diabetes-related technology: editorial overview. In: Bradley C, Home P, Christie M (ed), *The technology of diabetes care*. Chur: Harwood Academic, 1991, 1-7.
150. Brewin CR, Bradley C, Home PD. Measuring need in patients with diabetes. In: Bradley C, Home P, Christie M (ed), *The technology of diabetes care*. Chur: Harwood Academic, 1991, 142-155.
151. Home PD. Implantable insulin infusion pumps in the management of diabetes. In: Bradley C, Home P, Christie M (ed), *The technology of diabetes care*. Chur: Harwood Academic, 1991, 73-83.

Book - 1991

152. Tunbridge WMG, Home PD. *Diabetes and endocrinology in clinical practice*. London: Edward Arnold, 1991.

Books edited - 1991

153. C Bradley, P Home, M Christie. *The technology of diabetes care*. Chur: Harwood Academic, 1991.
154. Home PD. *2nd International Copenhagen symposium on Type 2 diabetes*. Amsterdam: Medicom, 1991.

Reviewed articles - 1992

155. Monti LD, Piatti PM, Home PD, Tomson C, Alberti KGMM. The effect of intraperitoneal insulin delivery on carbohydrate metabolism in type 1 (insulin-dependent) diabetic patients. *Diabetes Res Clin Pract* 1992; 15: 237-244.
156. Gazzaz ZJA, Home Philip D, Alberti KGMM. The reliability of the oral glucose tolerance test in subjects with varying degree of glucose intolerance in Saudi Arabia. *International Diabetes Digest* 1992; 3: 71-75.
157. Lawrence GP, Home PD, Murray A. Repeatability of measurement and sources of variability in cardiovascular autonomic function tests. *Br Heart J* 1992; 68: 205-212.
158. Robertson DA, Tunbridge FKE, John WG, Home PD, Alberti KGMM. Diagnostic confusion in diabetes with persistence of fetal haemoglobin. *Br Med J* 1992; 305: 635-637.
159. Lawrence GP, Home PD, Murray A. Autonomic function testing in diabetic subjects using sequential measurement. *Diabetic Med* 1992; 9: 799-805.
160. Kruszynska, YT, Munro J, Home PD, McIntyre N. Twenty-four hour C-peptide and insulin secretion rates and diurnal profiles of glucose, lipids and intermediary metabolites in cirrhosis. *Clin Sci* 1992; 83: 597-605.
161. Carson ER, Home PD, Massi-Benedetti M, Piwernetz K, Vaughan NJA, for the DOIT Study Group. Recommendations to facilitate the implementation of the St Vincent Declaration initiatives by national, regional, and local task forces. *Diabetes Nutrit Metabol* 1992; 5: 141-150.
162. Akinmokun A, Harris P, Home PD, Alberti KGMM. Is diabetes always diabetes? *Diabetes Res Clin Pract* 1992; 18: 131-136.
163. Williams DRR, Home PD, for the Working Group of the Research Unit of the Royal College of Physicians and the British Diabetic Association. A proposal for continuing audit of diabetes services. *Diabetic Med* 1992; 9: 759-764.
164. Deerochanawong C, Home PD, Alberti KGMM. A survey of lower limb amputation in diabetic patients. *Diabetic Med* 1992; 9: 942-946.
165. Azzopardi, E Barrett, W Gruber, P D Home, J Jervell, A de Leiva, M Massi-Benedetti, K Piwernetz, K Staehr Johansen. Recommendations to facilitate the implementation of St Vincent declaration initiatives by national, regional and local diabetes task forces. Copenhagen: World Health Organization, 1992.
166. White JES, Bullock RE, Hudgson P, Home PD, Gibson GJ. Phrenic neuropathy in association with diabetes. *Diabetic Med* 1992; 9: 954-956.
167. Thow JC, Coulthard A, Home PD. Ultrasonographic assessment of insulin injection site tissue depths and localization of injected bolus by novel air-contrast technique in insulin treated diabetic patients. *Diabetic Med* 1992; 9: 915-920.

Invited articles - 1992

168. Home PD. Diabetic Medicine: physiology of a journal. *Diabetic Medicine* 1992; 9: 7-8.
169. Home PD. Audit in diabetes care. *Update* 1992; 44: 385-386.
170. Home PD. T-cnicas para asegurarse de que su pr|ximo trabajo nunca se llegue a publicar. *Bolet/n Oficina Sanit Panamer* 1992; 113: 150-155.
171. Thow JC, Home PD. Insulin Injection Therapy. *Internat Diabetes Digest* 1991; 3: 82-85.
172. Home PD. Glycated haemoglobin and the monitoring of long-term blood glucose control. In, Mogensen CE, Standl E (ed), *Concepts of the ideal diabetes clinic*. Berlin: Walter de Gruyter, 1992, 187-198.
173. Home P. A depressing problem [editorial]. *Diabetic Med* 1992; 9: 285.

174. Home PD, Alberti KGMM. Insulin therapy. In: Alberti KGMM, De Fronzo RA, Keen H, Zimmet P (ed). International Textbook of Diabetes Mellitus. Chichester: John Wiley 1992: 831-863.

Reviewed articles - 1993

175. Kruszynska YT, Meyer-Alber A, Darakhshan F, Home PD, McIntyre N. Metabolic handling of orally administered glucose in cirrhosis. *J Clin Invest* 1993; 91: 1057-1066.
176. Bardsley MJ, Astell S, McCallum A, Home PD. The performance of three measures of health status in an outpatient diabetes population. *Diabetic Med* 1993; 10: 619-626.
177. European IDDM Policy Group 1993. Consensus Guidelines for the management of insulin-dependent (Type 1) Diabetes. *Diabetic Med* 1993; 10: 990-1005.
178. Harris PE, Walker M, Clark F, Home PD, Alberti KGMM. Forearm muscle metabolism in primary hypothyroidism. *Eur J Clin Invest* 1993; 23: 585-588.
179. Tunbridge FKE, Millar J, Schofield PJ, Spencer JA, Young G, Home PD. Diabetes care in general practice: an approach to audit of process and outcome. *Br J Gen Pract* 1993; 43: 291-295.
180. Wilson AE, Home PD for the Diabetic Audit Working Group of the Research Unit of the Royal College of Physicians and British Diabetic Association. A dataset to allow exchange of information for monitoring continuing diabetes care. *Diabetic Med* 1993; 10: 378-390
181. Piwernetz K, Home PD, Snorgaerd O, Antsiferov K, Staehr-Johansen K, Krans M for the DiabCare Monitoring Group of the St Vincent Declaration Steering Group. Monitoring the targets of the St Vincent Declaration and the implementation of Quality Management in diabetes care: the DiabCare initiative. *Diabetic Med* 1993; 10: 371-377.
182. Flack JR, Home PD. An approach to the use of the DOIT Study Group Guidelines for supporting the optimal implementation of information systems in diabetes care. *Diabetic Med* 1993; 10: 568-573.
183. Home PD. An adequate standard of care for diabetes. *J Med Defence Union* 1993; 9: 60-62.

Invited articles - 1993

184. Home PD. Implementation of the St Vincent Declaration in the United Kingdom. *G Ital Diabetologia* 1993; 13 (Suppl): 89-91.
185. Home P D. Database and diabetes: Dogsbodies or devils (Editorial). *Diabetic Med* 1993; 10: 303-304.
186. Diabetes Services Advisory Committee. Recommendations for the management of diabetes in primary care. London: British Diabetic Association, 1993.
187. Thow JC, Home PD. Nocturnal hypoglycaemia. In: Frier BM, Fisher BM (ed). *Hypoglycaemia and diabetes*. London: Edward Arnold, 1993, 199-211.
188. Home PD. How should we measure the quality of diabetes care? *Hospital Update* 1993; 44 (therapeutics review suppl): 11-12.

Book edited - 1993

189. Marshall SM, Home PD (ed). *Diabetes Annual 7*. Amsterdam: Elsevier, 1993.

Reviewed articles - 1994

191. Alexander W, Bradshaw C, Gadsby R, Home PD, Kopelman P, MacKinnon M, Redmond S, Vaughan N, for the British Diabetic Association. An approach to manageable datasets in diabetes care. *Diabetic Med* 1994; 11: 806-810.

192. Home PD. Diagnosing the undiagnosed with diabetes [editorial]. *Br Med J* 1994; 308: 611-612

Invited articles - 1994

191. Robertson DA, Home PD. Problems and pitfalls of sulphonylurea therapy in older patients. *Drugs Aging* 1993; 3: 510-524
192. Home PD. Advances in the Organization and Implementation of Diabetes Care. In, Marshall SM, Home PD (ed), *Diabetes Annual 8*. Amsterdam, Elsevier, 1994, In press.
193. Home PD. A Critique of the DCCT: Implications for Europe. *IDF Bulletin* 1994;
194. Home PD, Kruszynska YT, Tunbridge FKE. Insulin therapy, metabolic control and muscle enzymes in people with type 2 diabetes (NIDDM). In, Sakamoto N, Alberti KGMM, Hotta N (ed), *Pathogenesis and treatment of NIDDM and its related problems*. Amsterdam: Excerpta Medica, 1994, 125-134.
195. Clinical Standards Advisory Group. Standards of clinical care for people with diabetes. London: HMSO, 1994.

Book edited - 1994

196. Marshall SM, Home PD (ed). *Diabetes Annual 8*. Amsterdam: Elsevier, 1994.

Peer reviewed journals 1995

197. Kruszynska YT, Harry DS, Mohamed-Ali V, Home PD, Yudkin JS, McIntyre N. The contribution of proinsulin and des-31,32 proinsulin to the hyperinsulinemia of diabetic and nondiabetic cirrhotic patients. *Metabolism* 1995; 44: 254-260.
198. Home PD. Contributions respectives de la technique d'injection de l'insuline et de son absorption par voie sous-cutanée dans l'étiopathogénie des diabète dits instable. *J Ann Diabetol Hotel-Dieu* 1995; 243-255.
199. Home PD. Targets for glycated haemoglobin. Glycated haemoglobin targets are attainable [letter]. *Br Med J* 1995; 311:189.
200. Home P. A world of diabetes: all our problem [editorial]. *Diabetic Med* 1995; 12: 289-290.
201. Vaughan NJ, Home PD, for the Diabetes Audit Working Group of the Research Unit of the Royal College of Physicians and British Diabetic Association. The UK Diabetes Dataset: a standard for information exchange. *Diabetic Med* 1995; 12: 717-722.
202. Busch-Sorensen M, Elphick AJ, Home PD, Thorsteinsson B. Diabetes care: a guideline to the facilities needed to support internationally endorsed standards. *Diabetic Med* 1995; 12: 833-838.
203. International Diabetes Federation (Europe) and World Health Organization (Europe). The Acropolis Affirmation: diabetes care - St Vincent in progress. *Diabetic Med* 1995; 12: 636-636.
204. Home PD. Pharmacoeconomics of diabetes surveillance and detection programmes. *Pharmacoeconomics* 1995; 8 (suppl 1): 72-79.
205. Home PD. Economics of diabetes care must move forward [commentary]. *Br Med J* 1995; 311: 1599.
206. Piwernetz K, Home PD, Staehr Johansen K, Kleinbreil L, Vermeij D, Storms GEMG, Gallego MR, Massi-Benedetti M, Cowley C. DIABCARE quality network in Europe TELEMATICS project within the St Vincent declaration: consensus meeting. *Diabet Nutrit Metabol* 1995; 8: 243-249.

Non-peer reviewed journals 1995

207. DIABCARE Working Group of the St Vincent Declaration Steering Committee. Monitoring instruments for improving the quality of diabetes care. *G Ital Diabetologia* 1995; 15: 49-61.

208. World Health Organization. Implementation in practice. In King H, Gruber W, Lander T (ed), Implementing national diabetes programmes. Geneva: World Health Organization, 1995, 33-56.
209. Vaughan NJ, Home PD. The UK Diabetes Dataset: a standard for information exchange. *Diabetic Medicine* 12, 717-722
210. Keen, H; Alberti, KGMM; Alexander, WD; Betts, P; Burden, AC; Edmonds, ME; Fuller, JH; Home, PD; Jarrett, RJ; Kinmonth, AL; Diabetes in the United Kingdom-1996: A British Diabetic Association Report, London, British Diabetic Association, 1995.

Books edited 1995

210. Marshall SM, Home PD, Rizza RA (ed). The Diabetes Annual 9. Amsterdam: Elsevier, 1996.

Peer reviewed journals 1996

211. Buxton C, Gibby O, Hall M, Home PD, MacKinnon M, Murphy M, et al. Diabetes information systems: a key to improving the quality of diabetes care. *Diabetic Med* 1996; 13 (suppl 4): S122-S128.
212. Tooke J, Baker R, Burden M, Clark A, Dornan T, Gower J, Home P, Murphy M, Toy J. Report of the research and development group. *Diabetic Med* 1996; 13 (suppl 4): S77-S89.
213. Viberti, G-C, Marshall S, Beech R, Brown V, Derben P, Higson N, Home P, Keen H, Plant M, Walls J. Report on renal disease in diabetes. *Diabetic Med* 1996; 13 (suppl 4): S6-S12.
214. Home PD, Hallett L. Learning from St Vincent: Diabetes action programme paves the way for better health care. *IDF Bull* 1996; 41 (2): 6-9.
215. Bergrem H, Kalo I, Babic D, Home P, Staehr Johansen K. Diabetes care in Europe: the St Vincent declaration coming of age? *Diabet Nutrit Metabol* 1997; 9: 330-336
- 216 Rutter M, Home PD, Alberti KGMM. Fiveyear follow-up of cardiovascular risk factors in people with newly diagnosed Type II diabetes. *Diabet Nutrit Metabol* 1996; 9: 299-305.
217. Home P, Day J, Elphick T. Diabetes on the Old Silk Toad [editorial]. *Diabetic Med* 1996; 13: 207-208.

Non-peer reviewed journals / chapters 1996

218. Home PD. the mission of St Vincent: quality in European diabetes care [editorial]. *Practical Diabetes Internat* 1996; 13: 40.
219. Home PD. The nature and use of registers in diabetes care. In, Dawson A (ed) *Chronic Disease Management Registers*. London: HMSO, 1996, 80-89.
220. Wilson A, Wilbourne J, Home PD. Hospital audit of diabetes care. *Diabetic Nursing* 1996; 24: 12-16.

Books/supplements edited 1996

221. Marshall SM, Home PD, Rizza RA (ed). The Diabetes Annual 10. Amsterdam: Elsevier, 1996.
222. Home PD, Hallett L (ed). Special topic: Learning from St Vincent. *IDF Bull* 1996; 41 (2).

Peer reviewed journals 1997

223. Vaughan NJA, Jakenfelds J, Pinto FJ, Home PD. Diabetes:- the challenge for the next century. *IDF Bull* 1997 (1); 24-31.
224. European Arterial Risk Policy Group. Managing arterial risk in Type 2 (non-insulin-dependent) diabetes. *Diabet Med* 1997; 14: 611-621.

225. Canavan JP, Flecknell PA, New JP, Alberti KGMM, Home PD. The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM. *Diabetologia* 1997; 40: 1125-1134
226. Home PD. Insulin resistance is not central to the burden of diabetes. *Diabet Metabol Rev* 1997; 13: 87-92.
227. Home PD. The St. Vincent Declaration Initiative to improve conditions for people with diabetes in Europe. *Diabetologia* 1997; 40: B14-B15.
228. Johansen KS, Home PD, for the St Vincent Executive. Improving health of people with diabetes: The "end of the beginning" *Diabet Nutrit Metabol* 1997; 10: 126-163
229. Home PD. Intensive Insulin Therapy in Clinical Practice. *Diabetologia* 1997; 40 (suppl 2): S83-S87.

Non-peer reviewed journals / books 1997

230. Home PD. Insulin therapy. In: Alberti KGMM, De Fronzo RA, Zimmet P, Keen H, (ed), *International textbook of diabetes mellitus*, 2nd edition. Chichester: John Wiley, 1997, 899-928.
231. Keen H, Home PD. Organization of care: Europe and the St Vincent declaration initiative. . In: Alberti KGMM, De Fronzo RA, Zimmet P, Keen H, (ed), *International textbook of diabetes mellitus*, 2nd edition. Chichester: John Wiley, 1997, 1709-1718.
232. European Hypertension in Diabetes Working Group. Hypertension in people with Type 2 (non-insulin-dependent) diabetes. Brussels: International Diabetes Federation (Europe), 1997.
233. Home PD. Clinical management systems: focus on the patient. In, Home PD (ed). *Diabetes the Challenge*. Zeist: Medical Forum, 1997, 47-52.
234. Vaughan, NJA; Cashman, SJ; Home, PD; Vermeij, D; Sando, SH; The development of a generic message for use in diabetes care. *Diabetes Nutrit Metab* 1997; 10: 265-272.
235. World Health Organization. The Lisbon Statement. *Diabet Med* 1997; 14: 517-518.
236. deAlmeida, PP; Deleiva, A; Ericsson, A; Ferrannini, E; Green, A; Home, PD; Hemmann, D; Marshall, SM; Standl, E; Van Crombrugge, P. A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. *Diabet Med* 1997; 14: 611-621.
237. Johansen, KS; Home, PD; Berger, M; Massi Benedetti, M; Bergrem, H; Rink, HV; Improving health of people with diabetes: the "end of the beginning". *Diabetes Nutrit Metabol* 1997; 10: 126-163.

Books edited 1997

238. Home PD (ed). *Diabetes the Challenge*. Zeist: Medical Forum, 1997.

Peer reviewed journals 1998

239. Ahmed ABE, Home PD. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. *Diabetes Care* 1998; 21: 32-37.
240. Ahmed ABE, Mallias J, Home PD. Optimization of evening insulin dose in patients using the short-acting insulin analogue lispro. *Diabetes Care* 1998; 21: 1162-1166.
241. Johansen KS, Home PD, Berger M, Massi Benedetti M, Bergrem H, Rink HV. Improving the health of people with diabetes: the 'end of the beginning'. *Diabet Nutrit Metabol* 1977; 10 (suppl 3): 1-37
242. Ahmed ABE, Home PD. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. *Diabetes Care* 1998; 21: 1707-1713

243. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycaemic control with insulin aspart. *Diabetes Care* 1998; 21: 1904-1909
244. a. European Diabetes Policy Group, International Diabetes Federation, European Region. A desktop guide to type 1 (insulin-dependent) diabetes mellitus. *Exp Clin Endocrinol Diabet* 1998; 106: 240-269.
- b. European Diabetes Policy Group, International Diabetes Federation, European Region. A desktop guide to type 1 (insulin-dependent) diabetes mellitus. Brussels: International Diabetes Federation, 1998, 1-36.

Non-peer reviewed journals / books 1998

245. Home PD. Cost effective management of Type 1 diabetes. The fundholding and commissioning guide, volume II. London: Medical Information Systems, 1998, 145-147.
246. Home PD, Ahmed ABE. Insulin therapy. In, Marshall SM, Home PD, Rizza RA (ed), *The Diabetes Annual 11*. Amsterdam, Elsevier, 1998, 213-230.
247. Home P, Lauritzen T (ed). Optimising the use of ACE inhibitors in diabetes care. *Practical Diabetes* 1998; 15(8): S1-S5.
248. Home PD. Insulin therapy in Type 1 diabetes. In, Barnett A (ed), *The insulin treatment of diabetes; a practical guide*. London: Emap healthcare, 1998, 13-17.
249. Home PD, Keen H. Making Progress with Diabetes Care: a Story from the UK. *IDF Bulletin* 1998; 43: 8-12

Books edited 1998

250. Marshall SM, Home PD, Rizza RA (ed). *The Diabetes Annual 11*. Amsterdam: Elsevier, 1998.

Peer reviewed journals 1999

251. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. *Eur J Clin Pharm* 1999; 55: 199-203
252. Home PD. Rapid-acting insulin secretagogues: a clinical need? *Exp Clin Endocrinol Diabet* 1999; 107: S115-S119
253. European Diabetes Policy Group, International Diabetes Federation, European Region. A desktop guide to Type 2 diabetes mellitus.
- a. *Diabetic Med* 1999; 16: 716-730.
- b. Brussels: International Diabetes Federation, 1999.
- c. *Medycyna Praktyczna* 1999; 10 (suppl 104).
- (also versions in Turkish, Georgian, Russian, Italian, German, Uzbek, Latvian, and others)
254. Home P. Is prandial glucose regulation important in Type 2 diabetes? *JAMA SE Asia* 1999; 15 (suppl 1): 7
255. Home P. The St Vincent Declaration Initiative. *JAMA SE Asia* 1999; 15 (suppl 1): 39
256. Home P. La régulation du glucose prandial est-elle importante dans le diabète de type 2? *Diabetes Metabol* 1999; 25: 20-21.

Non-peer reviewed journals / books 1999

257. Home PD. Insulin glargine: the first clinically useful extended-acting insulin in half a century? *Exp Opin Invest Drugs* 1999; 8: 307-314.
258. Home P. Insulin aspart. *Drugs* 1999; 57: 766-767

259. Home PD, Coles J, Goldacre M, Mason A, Wilkinson E (Ed). Health outcome indicators: diabetes. Report of a working group to the Department of Health. Oxford: National Centre for Health Outcomes Development, 1999.
260. St Vincent Declaration Working Group. Implementation of national diabetes programmes. Copenhagen: World Health Organization, 1999
261. Home PD, Schatz H. Repaglinide: a new dimension in the management of Type 2 diabetes. *Exp Clin Endocrinol Diabet* 1999; 107 (suppl 4): S115-S148.
262. Home PD. Management of Type 2 diabetes into the next millennium: practical applications within Europe. *Diabet Obesity Metabol* 1999; 1 (suppl 2).
263. Heinemann L, Home P. Adis New Drug Profiles-Insulin Aspart: Viewpoints. *Drugs* 1999; 57; 5: 766-768.

Books edited 1999

264. Marshall SM, Home PD, Rizza RA. *Diabetes Annual / 12*. Amsterdam: Elsevier, 1999.

Peer reviewed journals 2000

265. Home PD, Lindholm A, Riis A, for the European Insulin Aspart Study Group. Insulin aspart versus human insulin in the management of long-term blood glucose control in Type 1 diabetes: a randomized controlled trial. *Diabet Med* 2000; 17: 762-770.
266. Home PD. Rapid-acting insulin analogues: when randomized clinical trial results do not help. *Diabet Med* 2000; 17 (suppl 2): 6-8.

Non-peer reviewed journals/chapters 2000

267. Gallagher A, Home PD. Humalog Mix25: first insulin analogue mixture. *Prescriber*. 2000; 11(6): 107-110.
268. Home PD. Arterial risk management in Type 2 diabetes. *Post Grad Med* 2000; 14: 349-367.
269. Home PD. *Insulin therapy: new concepts and new tools*. Bangalore: Novo Nordisk, 2000.
270. Hutchinson A, McIntosh A, Feder G, Home PD, Young R, for the Foot Care Working Group. *Clinical guidelines for Type 2 diabetes. Prevention and management of foot problems*. London: Royal College of General Practitioners, 2000.
271. Home PD. Postprandial hyperglycaemia: mechanisms and importance. *Diabet Obesity Metabol* 2000; 2 (suppl 1) S7-S11
272. Home PD. Insulin Glargine. *Drugs* 2000; 59: 261-262.

Peer reviewed journals 2001

273. Ramtoola S, Home PD, Damry H, Husnoo A, Ab-Kion S. Gestational impaired glucose tolerance does not increase perinatal mortality in a developing country: cohort study. *BMJ* 2001; 322: 1025-1026
274. Ahmed ABE, Badgandi M, Home PD. Interval between insulin injection and meal in relation to glycosylated haemoglobin. *Pract Diabet Int* 2001; 18: 51-56
275. Home PD. Therapeutic targets in the management of Type 1 diabetes. *Diabet Metab Res Rev* 2001; 17 (suppl 2): S1-S9.
276. Ashwell SG, Home PD. Insulin glargine: the first clinically useful extended-action insulin analogue. *Exp Opin Pharmacother* 2001; 2: 1891-1902.

Non-peer reviewed journals/books 2001

277. Home PD. A brief history of insulin therapy. In Barnett AH (ed), *Insulin made easy*. Medical Education Partnership, 2001, 7-14.

278. Home PD. Organisation of diabetes care. In, Wass JAH, Shalet SM (ed), Oxford Textbook of Endocrinology. Oxford: Oxford University Press, 2001
- 279 McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, Davis R, Field R, Frost G, Marshall S, Roddick J, Tesfaye S, Withers H, Suckling R, Smith S, Griffin S, Kaltenthaler E, Peters J, Feder G. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield 2001. <http://www.nice.org.uk>

Peer reviewed journals 2002

280. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. *Diabet Med* 2002; 19: 393-9.
281. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. *Diabetes Care* 2002; 25: 876-82.
282. Home P. Chacra A. Chan J. Emslie-Smith A. Sorensen L. Van Crombrugge P. Boulton A. Davidson J. Dornan T. Heine R. Jimenez J. Kangas T. Kawamori R. Landgraf R. Massi-Benedetti M. Mogensen CE. Christiansen JS. Skyler J. Sorensen L. Uccioli L. Van Crombrugge P. Considerations on blood glucose management in type 2 diabetes mellitus. *Diabet Metabol Res Rev* 2002; 18: 273-285.
283. Working Party of the International Diabetes Federation (European Region) (chair Home PD). Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. *Diabet Med* 2003; 20: 972-987.
284. Home PD, Ashwell SG. An overview of insulin glargine. *Diabet Metab Res Rev* 2002; 18 (suppl 3): S75-S63.
285. Home PD. Therapeutic targets in the management of type 1 diabetes. *Diabet Metabol Res Rev* 2002; 18 (suppl 1); S7-S13.

Non-peer reviewed journals/books 2002

286. Home PD. Thiazolidenediones: increasing insulin sensitivity. In, Amiel S, Horizons in Medicine, volume 13. London: Royal College of Physicians, 2002, 185-194.
287. McIntosh A Hutchinson A Marshall S Barnes D Brown V Hopper S Nicholls A Peters J, Viberti GC, Walker J, Feder G, Home PD (2002) Clinical Guidelines and Evidence Review for Type 2 Diabetes. Renal Disease: Prevention and Early Management. Sheffield: ScHARR, University of Sheffield, 2002. (Also www.nice.org.uk)
288. Marshall SM, Home PD, Manley SE, Barth JH, John WG. Standardization of glycated haemoglobin. *Diabet Med* 2002; 19: 429, and *Ann Clin Biochem* 2002; 39: 78-9.
289. Home PD. Editorials:
- a Vociferous about diabetes. *Diabetes Voice* 2002; 47 (1): 3.
 - b The changing face of guidelines. *Diabetes Voice* 2002; 47 (2): 1.
 - c The life-cycle of a woman's diabetes. *Diabetes Voice* 2002; 47 (special issue: Women and diabetes): 3.
 - d Learning diabetes. *Diabetes Voice* 2002; 47 (3): 3
 - e Global danger from pharmaceutical regulation. *Diabetes Voice* 2002; 47 (4): 3
290. Home PD. Expensive new drugs: NICE , or not so nice? *Diabetes Voice* 2002; 47 (2): 33-36.
291. Home PD. The drug dilemma. *Diabetes Voice* 2002; 47 (special issue Women and diabetes): 14-15.

292. McIntosh A, Hutchinson A, Feder G, Durrington P, Elkeles R, Hitman GA, Robson J, Home P, Peters J, Pandor A, Kaltenthaler E. Clinical guidelines and evidence review for Type 2 diabetes: Lipids Management. Sheffield: SchHARR, University of Sheffield, 2002.
293. Reinauer, H; Home, PD; Kanagasabapathy, AS; Heuck CC. Laboratory diagnosis and monitoring of diabetes mellitus. Geneva: World Health Organization, 2002

Peer reviewed journals 2003

294. De Vries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. *Diabet Med* 2003; 20: 312-318.
295. Home P. The challenge of poorly controlled diabetes mellitus. *Diabet Metabol* 2003; 101-109.
296. Home PD. Boulton AJM. Jimenez J. Landgraf R. Osterbrink B. Christiansen JS. Issues relating to the early or earlier use of insulin in type 2 diabetes. *Pract Diabet Internat* 2003; 20 (2): 63-71.
297. De Backer, G; Ambrosioni, E; Borch-Johnsen, K; Brotons, C; Cifkova, R; Dallongeville, J; Ebrahim, S; Faergeman, O; Graham, I; Mancia, G; European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). *Eur Heart J* 2003; 24: 1601-1610.

Non-peer reviewed journals/books 2003

298. McIntosh A, Peters J, Young R, Hutchinson A, Chiverton R, Clarkson S, Foster A, Gadsby R, O'Connor M, Rayman G, Feder G, Home PD. Prevention and management of foot problems in Type 2 diabetes: Clinical guidelines and evidence. Sheffield: University of Sheffield, 2003. (Also summarized as NICE guideline 2004, www.nice.org.uk)
299. Home PD. PPAR- γ modulators: their role in diabetes care. In Raz I, Skyler J, Shafir E (ed), *Diabetes: from research to diagnosis and treatment*. London: Martin Dunitz, 2003, 347-362
300. Home PD. Diabetes Voice editorials:
- a A diabetes presence. *Diabetes Voice* 2003; 48 (1): 3
 - b Where next for IDF? *Diabetes Voice* 2003; 48 (2): 3
 - c Prevention comes of age. *Diabetes Voice* 2003; 48 (prevention): 3
 - d It's all kidneys. *Diabetes Voice* 2003; 48 (kidneys): 3
 - e Diabetes beyond health care. *Diabetes Voice* 2003; 48 (3): 3
 - f The very centre of care. *Diabetes Voice* 2003; 48 (4): 3
301. Home PD. Going down: lipids and all that cholesterol. *Diabetes Voice* 2003;; 48 (prevention); 47-48.
302. Home PD. A guide to guide diabetes guideline development. *Diabetes Voice* 2003; 48 (3):18-20.

Peer reviewed journals 2004

303. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E. Insulin detemir offers improved glycemic control compared with NPH Insulin in people with Type 1 Diabetes. *Diabetes Care* 2004; 27: 1081-1087.
304. Boehm BO, Vaz JA, Brondsted L, Home PD. Long term efficacy and safety of biphasic insulin aspart in people with Type 2 diabetes. *Eur J Int Med* 2004; 15: 496-502.

305. Consoli A, Gomis R, Halimi S, Home PD, Mehnert H, Strojek K, Van Gaal LF. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications. *Diabet Metab* 2004; 30 509-516.
306. Home PD, Mbanja J-C, Horton E. Standardization of glycated haemoglobin. *BMJ* 2004; 329, 1196-1197.

Non-peer reviewed journals/books 2004

307. The National Collaborating Centre for Chronic Conditions. Type 1 diabetes in adults (Home PD, clinical lead). London: Royal College of Physicians, 2004
308. Smith SC Jr, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, Wood DA, Alderman M, Horgan J, Home P, Hunn M, Grundy SM. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. *Circulation* 2004; 109: 3112-21.
309. International Diabetes Federation Clinical Guidelines Task Force (Home PD, chair). Guide for guidelines: A guide for clinical guidelines development. Brussels: International Diabetes Federation, 2004. (www.idf.org)
310. Home PD. Diabetes Voice editorials:
- a Not the blank slate. *Diabetes Voice* 2004; 49 (1): 3
 - b Deaths from diabetes. *Diabetes Voice* 2004; 49 (2): 3
 - c It's all about the people. *Diabetes Voice* 2004; 49 (special issue: People with diabetes): 3
 - d Diabetes Care in need. *Diabetes Voice* 2004; 49 (3): 3
 - e Understanding the evidence. *Diabetes Voice* 2004; 49 (special issue: Eating): 3
- 311 Home PD. Glucose: sweetness and toxin. *Diabetes Voice* 2004; 49 (special issue: Eating): 5-7.

2005

312. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. *Diabet Res Clin Pract* 2005; 67: 196-203.
313. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas M, Jones NP. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. *Diabetologia* 2005; 48: 1726-35. <http://dx.doi.org/10.1007/s00125-005-1869-1>
314. Wilkinson A, Davidson J, Dotta F, Home P, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregrosa J-V, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. *Clin Transplant* 2005; 19: 291-298.
315. Home PD, R Roskamp, J Forjanic-Klapproth, A Dressler, for the European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. *Diabetes Metab Res Rev* 2005; 21; 545-553.

Non-peer reviewed journals/books 2005

316. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. *Curr Med Res Opin* 2005; 21: 989-996.

317. International Diabetes Federation Task Force on Clinical Guidelines [Home PD, Chair]. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005. www.idf.org
318. Diabetes UK. Recommendations for the provision of services in primary health care for people with diabetes. London: Diabetes UK, 2005.
319. Home PD, Home EM. International textbook of diabetes mellitus. [Book review.] *Diabet Med*. 2005; 22: 1460-1460.
320. Thomas R, Home PD. Insulin therapy for people with Type 1 diabetes. *Prescriber* 2005; 16 (6): 48-58.

2006

321. Ashwell, J Gebbie, PD Home. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. *Diabet Med* 2006; 23: 46-52.
322. Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler DA, Stephens WA, Home PD. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabet Med* 2006; 23: 285-292.
323. Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. *Diabet Res Clin Pract* 2006; 71: 131-139. doi:10.1016/j.diabres.2005.05.015
324. Hanney SR, Home PD, Frame I, Grant P, Green P, Buxton MJ. Identifying the impact of diabetes research. *Diabet Med* 2006; 23: 176-184. doi:10.1111/j.1464-5491.2005.01753.x
325. Home PD, Kurtzhals P. Insulin detemir: from concept to clinical practice. *Expert Opinion on Pharmacotherapy* 2006; 7: 325-43.
326. Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. *Pharmacoeconomics* 2006; 24 (suppl 1) 5-19.
327. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. *Diabetic Med* 2006; 23: 879-886.
328. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P, on behalf of the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care* 2006; 29: 1269-1274.
329. IDF Clinical Guidelines Task Force [Home PD, Chair]. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive and minimal care. *Diabet Med* 2006; 23: 579-593.
330. Home PD. Cost-effectiveness of CSII (Letter). *Diabet Med* 2006; 23: 707-707.
331. Sibal L, Law HN, Gebbie J, Home PD. Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with Type 1 diabetes: a 10-year follow-up study. *Ann NY Acad Sci* 2006; 1084: 304-318.
332. Sibal L, Law HN, Gebbie J, Dashora UK, Agarwal SC, Home PD. Predicting the development of macrovascular disease in people with Type 1 diabetes: a 9-year follow-up study. *Ann NY Acad Sci* 2006; 1084: 191-207.
333. Home P. The diabetes epidemic and the developing world. *Practical Diabetes International* 2006; 23 (8): 325-326.
334. IDF Clinical Guidelines Task Force [Home PD, Chair]. A digest of the Global Guideline for Type 2 Diabetes. *Diabetes Voice* 2006; 51 (supplement): 1-44.

335. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization, 2006. www.who.int/diabetes/publications/en/
336. Komajda, M; Grimaldi, A; Home, PD; Beck-Nielsen, H; Curtis, P; Zambanini, A; Dargie, H. Prolonged efficacy on 12 months of rosiglitazone given in association on ambulatory arterial stiffness in patients suffering type 2 diabetes. *Diabetes Metab* 2006; 32: 1S78-1S80

2007

337. Gallagher A, Butler TJ, Home PD. The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. *Diabet Res Clin Practice* 2007; 76: 327–334.
338. Dashora UK, Sibal L, Ashwell SG, Home PD. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomised placebo-controlled trial. *Diabet Med* 2007; 24: 344–349. doi: 10.1111/j.1464-5491.2007.02094.x
339. Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone+metformin therapy when starting insulin therapy in people with type 2 diabetes. *Diabet Med* 2007; 24: [accepted 21 November 2006] doi: 10.1111/j.1464-5491.2007.02141.x
340. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P, for the RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. *Diabet Med* 2007; 24: 626-634.
341. Al-Ozairi E, Sibal S, Home P. ADOPT: Good for sulfonylureas? *Diabetes Care* 2007; 30: In press; published on line 10 March 2007
342. Home PD. Comment on Nauck MA et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study published in "Diabetologia". [Letter.] dx.doi.org/10.1007/s00125-007-0653-9
343. Davis MD, Beck RW, Home PD, Sandow J, Ferris FL. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH insulin. *Exp Clin Endocrinol Diabetes* 2007; 115: 240-243. doi: 10.1055/s-2007-970577
344. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV, for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. *N Engl J Med* 2007; 357: 28-38
345. Thomas R, Home P. Current insulin therapies for people with Type 1 diabetes. *Prescriber*, 2007; December: 25-34.
346. Al-Ozairi E, Home P. New therapies in the management of type 2 diabetes. In, Lomas, D (ed), *Horizons in medicine* 19. London: Royal College of Physicians, 2007, 257-266
347. Home P, Bagust A, Taylor M, Ambery P, Mendes da Dosta S. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. *Pharmacoeconomics* 2007; 25: 801–802.

2008

348. Home PD, Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. *Diabet Obesity Metabol* 2008; 10: 699-718. doi: 10.1111/j.1463-1326.2007.00761.x
349. Rosenstock J, Davies M, Home PD, Larsen J, Koenen, C, Scherthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia* 2008; 51: 408-416. doi 10.1007/s00125-007-0911-x

350. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD, for The RECORD Study Group. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). *Cardiovascular Diabetology* 2008; 7:10. doi:10.1186/1475-2840-7-10
351. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. *Diabetes Care* 2008; 31: 1112-1117.
352. Home PD. Safety of very tight blood glucose control in type 2 diabetes. *BMJ* 2008; 336: 458-459.
353. Home P, Mant J, Diaz J, Turner C, on behalf of the Guideline Development Group. Management of type 2 diabetes: updated NICE guidance. *BMJ* 2008; 336: 1306-1308. doi:10.1136/bmj.39560.442095.AD
354. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: National clinical guideline for management in primary and secondary care (update). London, Royal College of Physicians, 2008. www.nice.nhs.uk
- National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes. London, National Institute for Health and Clinical Excellence, Clinical guideline 66, 2008. www.nice.nhs.uk
- National Institute for Health and Clinical Excellence. Quick reference guide Type 2 diabetes: the management of type 2 diabetes. London, National Institute for Health and Clinical Excellence, Clinical guideline 66, 2008. www.nice.nhs.uk
355. Home, PD. HbA_{1c}: the case for using estimated average glucose (eAG). *Diabet Med* 2008; 25: 895–898. doi: 10.1111/j.1464-5491.2008.02516.x
356. a. Home, PD. Impact of the UKPDS – an overview. *Diabet Med* 2008; 25 (suppl 2): 2-8. doi: 10.1111/j.1464-5491.2008.02501.x
- b. Home, PD. Impact of the UKPDS – an overview. In, Holman RR, Watkins PJ (ed), *UKPDS the first 30 years*. Chichester: Wiley-Blackwell, 2008, 125-136.
357. The SMBG International Working Group. Self-monitoring of blood glucose in type 2 diabetes: An inter-country comparison. *Diabet Res Clin Practice* 2008; 82: e15-e18. doi:10.1016/j.diabres.2008.08.021
358. Home P. Tight control of blood glucose and cardiovascular disease. (editorial) *BMJ* 2008; 337: a2105. doi: 10.1136/bmj.a2105 1007-1008
359. Siminerio L, Home P. Innovation, inspiration and an integrated approach – the World Diabetes Congress, Montreal, 2009. *Diabetes Voice* 2008; 53 (3): 37-39.
360. Thomas, R; Home, P. Managing insulin therapy. *Prescriber* 2008; 19(5): 21-23.
- 361 Home PD. HbA_{1c}: the case for using estimated average glucose (eAG). *Diabetic Med* 2008; 25: 895-898.

2009

362. Home P. Surgery and the prevention of limb loss in diabetes. *Brit J Surg* 2008; 96: 277-278. doi 10.1002/bjs.6573
363. Dashora U, Ashwell SG, Home PD. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. *Diabet Obesity Metabol* 2009; 11: 680-687. doi: 10.1111/j.1463-1326.2008.01024.x
364. Bolli G, Kerr D, Thomas R, Torlone E, Gazagnes S, Vitacolonna E, Home P. Comparison of a multiple daily insulin injection regime (basal once-daily glargine plus mealtime lispro) and

CSII (lispro) in type 1 diabetes: a randomized open parallel multicenter study. *Diabetes Care* 2009; 32:1170-1176. doi: 10.2337/dc08-1874

365. Sibal L, Aldibbiat A, Agarwal SC, Mitchell G, Oates C, Razvi S, Weaver JU, Shaw JA, Home PD. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness, and circulating markers of endothelial dysfunction in people with Type 1 diabetes without macrovascular disease or microalbuminuria. *Diabetologia* 2009; 52: 1465-1473. doi 10.1007/s00125-009-1401-0
366. Sibal L, Agarwal SC, Schwedhelm E, Luneburg N, Boger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. *Cardiovasc Diabetol* 2009; 8-27: 1-7.
367. National Institute for Health and Clinical Excellence. Type 2 diabetes - the management of type 2 diabetes (partial update). Clinical Guideline 87. London: National Institute for Health and Clinical Excellence, 2009. <http://guidance.nice.org.uk/CG87>.
368. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009; 373: 2125-2135. doi:10.1016/S0140-6736(09)60953-3.
369. Sibal L, Home P. Management of type 2 diabetes: the NICE guidelines. *Clin Med* 2009; 9: 353-357.
370. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. *Diabetologia* 2009; 52: 2499-2506. doi 10.1007/s00125-009-1530-5.
371. IDF Clinical Guidelines Task Force. Oral health for people with diabetes. Brussels: International Diabetes Federation, 2009.
372. Arutcheviam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins. *Diabet. Med* 2009; 26, 1027–1032.
373. Blonde, L; Home, P; Vespasiani, G; Admane, K; Marre, M. Patterns of cardiovascular risk and disease amongst people with type 2 diabetes starting insulin: baseline characteristics in the CREDIT study *Can J Diabetes* 2009; 33: 297-298.

2010

374. Sibal L, Neely RDG, Jones A, Home PD. Friedewald equation underestimates LDL-cholesterol at low concentrations in young people with and without Type 1 diabetes. *Diabet Med* 2010; 27: 37-45. doi 10.1111/j.1464-5491.2009.02888.x
375. Shakoor SKA, Aldibbiat A, Ingoe LE, Campbell SC, Sibal L, Shaw J, Home PD, Razvi S, WeaverJU. Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy. *J Clin Endocrinol Metab* 2010; 95: 319-322.
376. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. *Int J Clin Prac* 2010; 64: 1609-1618.
377. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, ADOPT Study Group, RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. *Diabetologia* 2010; 53: 1838-1845.
378. Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. *European Heart Journal* 2010; 31: 824-831.

379. Home PD. How can observational trials inform and improve clinical practice?. *Diabetes Res Clin Pract* 2010; 88 (suppl 1): S1-S2.
380. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. *Diabetes Obes Metab* 2010; 12: 772-779.
381. Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. *Diabetes Res Clin Pract* 2010; 88 (suppl 1) s3-s9.
381. Home PD. Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance. *Evid Based Med* 2010; doi:10.1136/ebm1128, 1-2.
382. Thomas R, Home P. Recommended management of type 1 diabetes with insulin. *Prescriber* 2010; 21 (14): 14-22.
383. Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. *Curr Med Res Opin* 2010; 26: 1621-1628.
384. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. *Curr Cardiol Rev* 2010; 6: 82-90. doi: 10.2174/157340310791162659
385. National Diabetes Care Guidelines Advisory Board. *Libyan Diabetes Care Guidelines, 2010*, Hajjaji IM, Colagiuri S, Home PD (ed). https://www.researchgate.net/publication/312638444_libyan_diabetes_care_guidelines_2010-2012

2011

386. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared to insulin glargine. *Diabetes Care* 2011; 34: 661-665.
387. Sibal L, Agarwal S, Home P. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. *Diabetes Metabolic Syndr Obes: Targets Therapy* 2011; 4: 23-34. doi 10.2147/DMSO.S8540
388. Home PD. Safety of PPAR agonists. *Diabetes Care* 2011; 34: (suppl 2): S215-S219.
389. Teoh H, Home P, Leiter LA. Should A1C targets be individualized for all people with diabetes? Arguments for and against. *Diabetes Care* 2011; 34 (suppl 2): S191-S196.
390. Little, S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. *Diabetes Technol Therapeut* 2011; 13 (suppl 1): S53-S64. doi:10.1089/dia.2011.0022.
391. National Institute for Health and Clinical Excellence Quality Standards Programme. Quality standard for diabetes in adults. London, NICE, 2011. www.nice.org.uk/media/FCF/87/DiabetesInAdultsQualityStandard.pdf
392. MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JVJ. Incidence and prevalence of unrecognised myocardial infarction in patients with diabetes mellitus: a sub-study of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study. *Diabetes Care* 2011; 34: 1394-1396. doi: 10.2337/dc10-2398
393. Hall GC, McMahon AD, Dain MP, Home PD. A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. *Diabet Res Clin Pract* 2011; 94: 442-448.
394. Home P. Biosimilar insulins. *Diabetes Voice* 2011; 56 (3), 40-43.

395. Home P. Structured care for diabetes should cover a spectrum of areas. *Guidelines in Practice* 2011; 11 (9):
http://www.eguidelines.co.uk/eguidelinesmain/gip/vol_14/sep_11/home_diabetes_sep11.php
396. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Yang W. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. *Diabetes Res Clin Pract* 2011; 94: 352–363.

2012

397. Home P. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes. *Diabetes Technol Therapeut* 2012, 14 (S1): S-33-S-42. doi:10.1089/dia.2012.0007
398. Lepercq J, Lin J, Hall G, Dain M-P, Riddle M, Home P. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine vs. NPH insulin during pregnancy. *Obstet Gynecol Int* 2012; 649070: 1-11 doi:10.1155/2012/649070
399. Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. *Diabet Med* 2012; 29: 716–720. doi: 10.1111/j.1464-5491.2011.03547.x
400. Home P. Diabetes therapy and prevention of vascular damage. In, Goodfellow JA (ed), *Understanding medical research: the studies that shaped medicine*. Chichester, Wiley-Blackwell, 2012, 235-245.
401. Hall GC, McMahon AD, Carroll D, Home PD. Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. *PLoS ONE* 2012; 7: e49908. doi:10.1371/journal.pone.0049908
402. Hall GC, McMahon AD, Carroll D, Home PD. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. *Pharmacoepidem Drug Safety* 2012; 21: 305–313. doi: 10.1002/pds.2345
403. Home PD, Almaatouq M. Improving health outcomes in 2011 for people with type 2 diabetes: A report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5–8 December 2011. *Brit J Diabetes Vasc Dis* 2012; 12: 101-108. doi: 10.1177/1474651412443389
404. N. Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, Kawamori R, Home PD. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. *Diabetes Obes Metab* 2012; 14: 901-909. doi: 10.1111/j.1463-1326.2012.01613.x
405. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Plüddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. *Diabetologia* 2012; 55: 2593-2603. DOI 10.1007/s00125-012-2653-7
406. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes Obes Metabol* 2012; 14: 780-788. doi: 10.1111/j.1463-1326.2012.01580.x
407. Clinical Guidelines Task Force. *Global guideline for type 2 diabetes*. Brussels: International Diabetes Federation, 2012. www.idf.org

2013

408. Home P. Insulin therapy and cancer. *Diabetes Care* 2013; 36 (suppl 2): S240-S244.
409. Hall GC, McMahon AD, Dain M-P, Wang E, Home P. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. *Diabet Med* 2013; 30: 681-686
410. Home P. Validity of meta-analysis in diabetes: we need to be aware of its limitations. *Diabetes Care* 2013; 36: 3361-3367.
411. Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JCN, Leiter LA, LeRoith D, DeFronzo R, Cefalu WT. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. *Diabetes Care* 2013; 36: 1779-1788; doi:10.2337/dc13-0512
412. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GETGOAL-L). *Diabetes Care* 2013; 36: 2489-2496.
413. Home P. Observational research: an integral part of enhancing diabetes management in south-east Asia. *Diabetes Res Clin Pract* 2013; 100 (suppl 1): S1-S2.
414. Lopes RD, Dickerson S, Hafley G, Burns S, Tourt-Uhlig S, White J, Newby K, Komajda M, McMurray J, Bigelow R, Home PD, Mahaffey KW. Methodology of a re-evaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. *Am Heart J* 2013; 208-216.
415. Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Lopes DR. Results of a re-evaluation of cardiovascular outcomes in the RECORD trial. *Am Heart J* 2013; 166: 240-249
416. Home PD, Latif ZA, González-Gálvez G, Prusty V, Hussein Z. The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A1chieve observational study. *Diabetes Res Clin Pract* 2013; 101: 326-332. doi: 10.1016/j.diabres.2013.06.005
417. Home P, Haddad J, Latif ZA, Soewondo P, Benabbas Y, Litwak L, Guler S, Chen J-W, Zilov A. Comparison of national/regional diabetes guidelines for the management of blood glucose control in non-western countries. *Diabetes Therapy* 2013; 4: 91-102. doi 10.1007/s13300-013-0022-2
418. Shah S, Yang W, Hasan MI, Malek R, Bech OM, Home P. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A₁chieve). *Diabetes Tech Ther* 2013; 15: 954-963. doi: 10.1089/dia.2013.0074
419. Freemantle N, Balkau B, and Home PD. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. *Diabetes Obes Metabol* 2013; 15: 1120-1127. doi: 10.1111/dom.12147.

2014

420. Home P, Riddle M, Cefalu W, Bailey CJ, Bretzel RG, Del Prato S, Le Roith D, Raz I, Schernthaner G, Van Gaal L. Insulin Therapy in People with Type 2 Diabetes: Opportunities and Challenges? *Diabetes Care* 2014; 37: 1499-1508. doi: 10.2337/dc13-2743.
421. Home P. The vexed question of hypoglycaemia and health economics. *Diabetes Obesity Metabolism* 2014; 16: 289-293.
422. Home PD, Shen C, Hasan MI, Latif ZA, Chen J-W, González Gálvez G. Predictive and explanatory factors of change in HbA_{1c} in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. *Diabetes Care* 2014; 37: 1237-1245. doi 10.2337/dc13-2413

423. Issam Hajjaji I, Shah S, Li Y, Prusty V, Benabbas Y, Home PD. Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with basal insulin: findings from the multinational, non-interventional A₁chieve study. *Diabetes Ther* 2014; 5: 113-126.
424. Dolinar RO, Edelman S, Heinemann L, Home PD, Goyal S, Polonsky WH, Schellekens H. Impact of biosimilar insulins on clinical practice. *J Diabetes Sci Technol* 2014; 8: 179-185.
425. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). *Heart* 2014; 100: ii1–ii67. doi:10.1136/heartjnl-2014-305693
426. Riddle MC, Bolli GB, Ziemien M, Muehlen-Bartmer I, Bizet F, and Home PD, on behalf of the EDITION 1 Study Investigators. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). *Diabetes Care* 2014; 37: 2755-6. doi: 10.2337/dc14-0991
427. Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. *Diabetes Care* 2014; 37: 2108-2113.
428. Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. *Diabetes Care* 2014; 37: 2647-2659. doi 10.2337/dc14-1395
429. Home P, Baik SH, Gálvez GG, Malek R, Nikolajsen A. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes. *J Med Econ* 2015; 18, 230-240.
430. Shafie AA, Gupta V, Baabbad R, Hammerby E, Home PD. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. *Diabetes Res Clin Pract* 2014; doi 10.1016/j.diabres.2014.08.024
431. Aschner, P; Beck Nielsen, H; Bennet, P; Boulton, A; Colagiuri, R; Colagiuri, S; Franz, M; Gadsby, R; Gagliardino, JJ; Home, P. Global guideline for type 2 diabetes. *Diabetes Res Clin Pract* 2014; 104; 1-52.

2015

432. Brooks AM, Oram R, Home P, Steen N, Shaw JAM. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation. *Diabetes Care* 2015; 38: 105-112.
433. Home PD, Bolli GB, Matheiu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain M-P, Riddle MC. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. *Diabetes Obes Metabol* 2015; 17: 15-22. doi: 10.1111/dom.12329
434. Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, Carr MC. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. *Diabetes Obesity Metab* 2015; 17: 179-187.
435. Home PD. A common fallacy of observational medication studies in diabetes. (Editorial.) *Diabetes Obesity Metab* 2015; 17: 317-318.
436. Jones NP, Curtis PS, Home PD. Cancer and bone fractures in observational follow-up of the RECORD study. *Acta Diabetologia* 2015; 52: 539-546.
437. Heinemann L, Khatami H, McKinnon R, Home P. An overview of current regulatory requirements for approval of biosimilar insulins. *Diabetes Tech Ther* 2015; 17: 510-26. doi 10.1089/dia.2014.0362

438. Bolli GB, Riddle MC, Bergenstal RM, Ziemer M, Sestakauskas K, Goyeau H, Home PD. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). *Diabetes Obes Metab* 2015; 17: 386-394.
439. Home PD, Dain M-P, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. *Diabetes Res Clin Pract* 2015; 108: 350-359. doi <http://dx.doi.org/10.1016/j.diabres.2015.01.030>
440. Riddle MC, Yki-Järvinen H, Bolli GB, Ziemer M, Muehlen-Bartmer I, Cissokho S, Home PD. One year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/mL compared with 100 U/mL in people with type 2 diabetes using basal + meal-time insulin (EDITION 1 12-month randomized trial including 6-month extension). *Diabetes Obes Metab* 2015; 17: 835-842. doi: 10.1111/dom.12472
441. Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Clinical Utility of SMBG: Recommendations on the use and reporting of self-monitoring of blood glucose (SMBG) in clinical research. *Diabetes Care* 2015; 38: 1627–1633.
442. Home PD, Bergenstal RM, Bolli GB, Ziemer M, Rojas M, Espinasse M, Riddle MC. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). *Diabetes Care* 2015; 38: 2217-25. doi: 10.2337/dc15-0249.
443. Heinemann L, Home PD, Hompesch M. Biosimilar insulins: guidance for data interpretation by clinicians and users. *Diabetes Obes Metab* 2015; 17: 911-918. doi: 10.1111/dom.12491
444. Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer X, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH. Advances in the science, treatment, and prevention of the disease of obesity reflections from a diabetes care editors' expert forum. *Diabetes Care* 2015; *Diabetes Care*. 2015; 38:1567-1582.
445. Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? *Diabetes Obes Metab* 2015; 17: 1011-1020. doi: 10.1111/dom.12501
446. Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study. *Diabetes Res Clin Pract* 2015; 108: 432-440.

2016

447. Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD. Relationship of glycaemic control and hypoglycaemic episodes to 4-year CV outcomes in people with type 2 diabetes starting insulin. *Diabetes Obes Metab* 2016; 18: 152–158. doi: 10.1111/dom.12598
448. Giorgino F, Home PD, Tuomilehto J. Glucose control and vascular outcomes in type 2 diabetes: is the picture clear? *Diabetes Care* 2016; 39 (suppl 2): S187–S195. doi 10.2337/dcS15-3023
449. Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemer M, Muehlen-Bartmer I, Wardecki M, Vinet L, Jeandidier N, Yki-Järvinen H. Efficacy and safety of flexible vs fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. *Diabetes Tech Therapeutics* 2016; 18: 252-257 <http://online.liebertpub.com/doi/10.1089/dia.2015.0290>
450. Christiansen JS, Home P, Kumar A. IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. *Exp Rev Endocrinol Metab* 2016; 11: 103-111. 10.1586/17446651.2016.1145541

451. Kumar A, Awata T, Bain SC, Ceriello A, Fulcher GR, Unnikrishnan AG, Arechavaleta R, Gonzalez-Gálvez G, Hirose T, Home PD, Kaku K, Litwak L, Madsbad S, Pinget M, Mehta R, Mithal A, Tambascia M, Tibaldi J, Christiansen JS. Clinical use of the co-formulation of insulin degludec and insulin aspart. *Int J Clin Pract* 2016; 70: 657-67. doi: 10.1111/ijcp.12821431.

2017

452. Home PD. Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. *Diabetes Obesity Metab* 2017; 9:304-305. doi: 10.1111/dom.12842
453. Home PD. Comment on Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems 2005–2011. *Diabetes Care* 2016; 39; 363–370. *Diabetes Care* 2017; 40: e1. doi: 10.2337/dc16-0527
454. Home P. A diabetes mellitus guideline gone wrong — the 2017 ACP update. *Nature Reviews Endocrinol* 2017; 13: 191-192. doi:10.1038/nrendo.2017.9
455. Home P. George Alberti: a myriad of contributions to diabetes and beyond. *Diabetes Care* 2017; 40: 1154-1158. doi 10.2337/dci17-0006
456. Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Role of continuous glucose monitoring (CGM) in clinical trials: recommendations on reporting. *Diabetes Tech Ther* 2017; 19: 391-399. doi 10.1089/dia.2017.0054
457. Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD; EDITION 3 study investigators. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. *Diabetes Metab.* 2017; 43: 351-358. doi: 10.1016/j.diabet.2017.04.007
458. Home PD, Ahren B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy. *Diabetes Res Clin Pract* 2017; 131: 49-60.
459. Blonde L, Marre M, Vincent M, Brette S, Pilorget V, Danchin N, Vespasiani G, Home P. Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. *Diabetes Res Clin Pract*; 2017: 133: 150-158.
460. Hirsch IB, Martinez J, Dorsey ER, Finken G, Fleming A, Gropp C, Home P, Kaufer DI, Papapetropoulos S. Incorporating site-less clinical trials into drug development: a framework for action. *Clin Ther* 2017; 39: 1064-1076.

2018

461. Riddle MC, Bolli GB, Avogaro A, Álvarez MG, Merino-Trigo A, Boëlle-Le Corfec E, Home PD. Assessment of hypoglycemia during basal insulin therapy: temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. *Diabetes Metab* 2018; 44, 333-340. doi: 10.1016/j.diabet.2017.12.001.
462. Home P, Shankar RR, Gantz I, Ireldale C, O’Niell EA, Jain J, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. *Diabetes Res Clin Pract*; 2018; 138: 253-261. doi: 10.1016/j.diabres.2017.10.018.

463. Home PD, Bergenstal RM, Bolli GB, Ziemer M, Rojas M, Espinasse M, Riddle MC. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). *Diabetes Obes Metab* 2018; 20: 121-128. doi: 10.1111/dom.13048.
464. Home P, Derwahl K-M, Ziemer M, Wernicke-Panten K, Pierre S, Kirchheim Y, Garg S. Anti-insulin antibodies and adverse events with biosimilar insulin lispro compared with humalog insulin lispro in people with diabetes. *Diabetes Tech Ther* 2018; 20:160-170.
465. Home P, Calvi-Gries F, Blonde L, Pilorget V, Berlingieri J, Freemantle N. Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. *Diabetes Obes Metab* 2018; 4: 921-929. doi: 10.1111/dom.13179.
466. The Beyond A1C Writing Group. Need for regulatory change to incorporate beyond A1C glycemic metrics. *Diabetes Care* 2018; 41: e92-e94. <https://doi.org/10.2337/dci18-0010>
467. Home PD, Lam RLH, Carofano WL, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rosenstock J, Hollander PA, Gallwitz B. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial. *Diabetes Obesity Metab* 2018; 20: 2220-2228. doi: 10.1111/dom.13354.
468. Home P, Lachin J. Comment on Novodvorsky et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. *Diabetes Care* 2018; 41: e64. <https://doi.org/10.2337/dc17-2405>
469. Hollander PA, Carofano WL, Lam RLH, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rendell MS, Home PD, Gallwitz B, Rosenstock J. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial. *Diabetes Obesity Metab* 2018; 20: 2229–2237. doi: 10.1111/dom.13363
470. Wang S, Neil D, Home P. 2020 vision – an overview of prospects for diabetes management and prevention in the next decade. *Diabetes Res Clin Pract* 2018; 143: 101-112. doi: 10.1016/j.diabres.2018.06.007.
471. Home P. A plan to hold back the diabetes tsunami. *Government Gaz* 2018; 3: 45.
472. Home P. Poisonous calories. *Kinexum spring 2018 newsletter*, pp 1-2. <http://www.kinexum.com/index.php/articles/466-spring-2018-newsletter-05-03-2018>

2019

473. Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB. Commencing insulin glargine 100 U/mL therapy in people with type 2 diabetes: Determinants of achievement of HbA1c goal <7.0%. *Diabetes Obes Metab* 2019; 21: 321–329. doi: 10.1111/dom.13607.
474. Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. *Diabetologia* 2019; 62: 357-369. doi: 10.1007/s00125-018-4801-1
475. Shavadia JS, Sharma A, Gu J, Neaton J, DeLeve L, Holmes D, Home P, Eckel RH, Watkins P, Granger CB. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. *Clin Trials* 2019; 16: 253-262. doi: 10.1177/1740774519836766
476. Klonoff DC, Aron D, Cohen RM, Home P, John WG, Little RR, Nathan D, Sacks DB. The need for accuracy in hemoglobin A1c proficiency testing: why the proposed CLIA rule of 2019 is a step backward. *J Diabetes Sci Technol* 2019; 13: 424-427. doi: 10.1177/1932296819841699
477. Home PD. Controversies for glucose control targets in type 2 diabetes: exposing the common ground. *Diabetes Care* 2019; 42: 1615-1623. doi: 10.2337/dci19-0002.

478. Home P. Meal-time + basal insulin therapy: is all not well? *Diabetes Res Clin Pract* 2019; 157: 107923 1-3. doi: 10.1016/j.diabres.2019.107923

2020

479. Home P, Itzhak B. Is insulin therapy safe? *Am J Ther* 2020; 27; e106–e114. doi: 10.1097/MJT.0000000000001077

480. Home P. How valid are the new clinical trial definitions of hypoglycaemia? *Diabetes Care* 2020; 43: 272-274. doi: 10.2337/dci19-0056

481. Bolli GB, Landgraf W, Bosnyak Z, Melas-Melt, L, Home PD. Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: a post hoc analysis of the EDITION 3 trial. *Diabetes Obese Metab* 2020; 22: 1664-1669. doi: 10.1111/dom.14065

482. Rosenstock J, Nino A, Soffer J, Erskine L, Acosta A, Dole J, Carr MC, Mallory J, Home P. Impact of a weekly GLP-1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. *Diabetes Care* 2020; 43: 2509-2518. doi: 10.2337/dc19-2316

483. Lu J, Home PD, Zhou J. Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy. *Diabetes Care* 2020; 43: e99-e101. doi: 10.2337/dc20-0561.

484. Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat M-M. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison. *Diabetes Obes Metab* 2020; 22: 2170-2178. doi: 10.1111/dom.14136

485. Home P. Letter to the Editor in Response to article: "Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)". *Diabetes Metab Syndr* 2020; 14; 417-417. doi: 10.1016/j.dsx.2020.04.002

486. Home P, Blonde L, Kalra S, Ji L, Guyot P, Brulle-Wohlhueter C, Murray E, Shah R, Sayre T, Shaunik A. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared to premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: a systematic review and Bayesian network meta-analysis. *Diabetes Obes Metab* 2020; 22: 2179-2188. doi: 10.1111/dom.14148.

487. Home P. Not too high, not too low: your blood pressure matters too. *diaTribe* 2020; 8/31/20. <https://diatribe.org/not-too-high-not-too-low-your-blood-pressure-matters-too>.

2021

488. Akirov A, Cahn A, Del Prato S, Home P, Van Gaal L, Chan J, Ning G, Raz I. Tackling obesity during the COVID-19 pandemic. *Diabetes Metab Res Rev* 2021; 37: e3393. doi: 10.1002/dmrr.3393.

489. Home P. The evolution of insulin therapy. *Diabetes Res Clin Pract* 2021; 175: On-line pre-print 20 April 2021. <https://doi.org/10.1016/j.diabres.2021.108816>.

490. Itzhak B, Home P. Heart failure management; a perspective from diabetes care. *Diabetes Res Clin Pract* 2021; 176: 1088449. doi: [org/10.1016/j.diabres.2021.108849](https://doi.org/10.1016/j.diabres.2021.108849).

500. Home P. Can we find out if COVID-19 causes diabetes? *Br J Diabetes* 2021; 21: 1-2. doi: 10.15277/bjd.2021.303.
501. Home P, Mehta R. Insulin therapy development beyond 100 years. *Lancet Diabetes Endocrinol* 2021; 9: 695-697. doi: 10.1016/S2213-8587(21)00182-0.
502. Riddle MC, Gerstein HC, Home PD. Lingering effects of hyperglycemia in recently diagnosed diabetes during long-term follow-up of the DCCT/EDIC and UKPDS cohorts: more evidence that early control matters. *Diabetes Care* 2021; 44: 2212-2215. doi: 10.2337/dci21-0030.
503. Home PD, Mehta R, Hafidh KAS, Gurova OY, Alvarez A, Serafini P, Pourrahmat M-M. Efficacy and safety of iGlarLixi versus IDegAsp: results of a systematic literature review and indirect treatment comparison. *Diabetes Obes Metab* 2021; 23: 2660–2669. doi: 10.1111/dom.14518.
505. Home PD. Future directions in insulin therapy. *Metab Clin Exp* 2021; 174: 154889. doi: 10.1016/j.metabol.2021.154889.

2022

506. Pagano D, Home P, Irs A, Ledermann J, Curigliano G, Iwatani T, Mandrola J, Freemantle N. The path for medical associations to sponsor trustworthy guidelines: is it feasible? *J Roy Soc Med* 2022; 115: 252–256. doi: 10.1177/01410768221095240.
507. Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O. Understanding biosimilar insulins – development, manufacturing, and clinical trials. *J Diabetes Sci Tech* 2022; final acceptance 23 May 2022.
508. McCrimmon RK, Home P, Cheng A, Giorgino F, Fonseca V, Souhami E, Alvarez A, Picard P, Rosenstock J. Hypoglycaemia events with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes advancing from basal insulin: an analysis of the SoliMix trial. *Diabetes Obes Metab* 2022; 24: 2391-2399. doi: 10.1111/dom.14825.
509. Home P. From muck to molecule: insulin discovery over 50 years. *Brit J Diabetes* 2022; 22 (suppl 1): S9–S12. doi: 10.15277/bjd.2022.3543

2023

510. Home PD, McCrimmon RJ, Rosenstock J, Blüher M, Pegelow K, Melas-Melt L, Djaballah K, Giorgino F, on behalf of the SoliMix trial investigators. Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. *Diabetes Obes Metab* 2023; On-line 30 October 2022. doi: 10.1111/dom.14907
511. Home P. Making sense of weekly insulins. *Lancet Diabetes Endocrinol* 2023; Accepted 22 December 2022.

Citation statistics (Google Scholar, January 2023)

	All	Since 2018
Citations	31907	9717
h-index	76	44
i10-index	274	128



